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Abstract 
Doxorubicin is a topoisomerase-targeting anthracycline that is one of the most 
effective anticancer drugs currently known. However, its clinical use is restricted by 
cardiotoxicity and the development of drug resistance. The main goal of this thesis 
has been to increase the knowledge of doxorubicin mechanism in addition to evaluate 
if predictive biomarkers for doxorubicin response could be identified. A total of 128 
tumor samples collected from breast cancer patients before and after neoadjuvant 
treatment with doxorubicin were studied. mRNA expression level in tumor tissue was 
assessed using whole-genome mRNA microarray analysis (Agilent Human GE 4x44K 
microarray). 
More than 5000 genes were found to be up- and down regulated following 
doxorubicin treatment.  The molecular and cellular functions as well as canonical 
pathways found to be enriched in the list of genes up regulated after doxorubicin 
exposure were involved in among other cardiovascular system development and 
function, cellular movement and immune responses. p53 was found to be the 
transcription factor regulating the highest number of target molecules within the list of 
up regulated genes. RNA processing, splicing and translation were shown to be 
overrepresented in the list of down regulated genes. The association between 
doxorubicin response and changes in gene expression revealed several genes such as 
CTGF, ITGB4 and IGF1 to be up regulated in the samples collected from patients 
characterized with a partial response to doxorubicin compared to those with minimal 
change and/or stable disease following treatment. In addition, the gene expression 
profiles between samples having wild type compared to mutated TP53 were studied, 
and a lower induction of expression were found for several genes such as FGF9 and  
COL11A2 in the samples having a mutated p53.  
This study showed that the gene expression profile in breast cancer tumors is altered 
as a response to doxorubicin exposure. Identifying genes significantly altered after 
therapy and associate their change with response to treatment may help identify the 
subgroup of patients benefitting from doxorubicin treatment. Patients with little or no 
effect of treatment could receive alternative therapy and be spared unnecessary 
treatment and risk of side effects.  
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Sammendrag 
Doxorubicin er et topoisomerase-hemmende antracyklin og er et av de mest effektive 
cytostatiske legemidlene brukt i kreftbehandling. Den kliniske bruken av doxorubicin 
er begrenset som følge av den irreversible kardiotoksiske effekten og pasienters 
utvikling av resistens. Hovedmålet med denne oppgaven har vært å øke forståelsen av 
de molekulærbiologiske mekanismene bak den cytotoksiske effekten av doxorubicin i 
tillegg til å prøve å identifisere prediktive biomarkører for doxorubicin respons. Totalt 
128 tumorprøver samlet inn fra brystkreftpasienter før og etter neoadjuvant 
behandling med doxorubicin ble studert. mRNA ekspresjonsnivå i tumorvev ble målt 
ved hel-genom mRNA mikromatrise analyse (Agilent Human GE 4x44K microarray). 
 
Mer enn 5000 gener ble funnet å være opp- og nedregulert etter doxorubicin 
behandling. De molekulære og cellulære funksjonene samt kurerte reaksjonsveiene 
som ble funnet overrepresentert i listen av gener oppregulert etter doxorubicin 
behandling var involvert i blant annet utvikling og funksjon av av hjerte-og 
karsystem, cellulær bevegelse og immunrespons. p53 ble funnet å være den 
transkripsjonsfaktoren som regulerte flest gener i listen med de oppregulerte genene. 
RNA prossesering, spleising og translasjon ble vist å være overrepresentert i listen 
med nedregulerte gener. Sammenhengen mellom doxorubicin respons og endringer i 
genuttrykket avdekket flere gener som CTGF, ITGB4 og IGF1 til å være oppregulert i 
tumorprøver fra pasienter som hadde en partiell respons til doxorubicin sammenlignet 
med dem som hadde en minimal endring og/eller stabil sykdom etter behandling. I 
tillegg ble ekspresjonsprofiler mellom prøver med villype sammenlignet med mutert 
TP53 studert, og en lavere induksjon i ekspresjon ble funnet for flere gener som 
FGF9 og COL11A2 i prøvene med mutert p53.  
 
Dette studie viser at ekspresjonsprofilen i brystkreftsvulster endres etter doxorubicin 
eksponering. Identifiseringen av gener signifikant endret som følge av behandling og 
sammenhengen mellom disse endringene mot respons på behandling kan bidra til å 
identifisere grupper av pasienter som kan ha utbytte av doxorubicin kjemoterapi. 
Pasienter med liten eller ingen effekt av behandlingen bør heller få alternativ terapi og 
bli spart for unødvendig behandling og risiko for bivirkninger.  
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1. Introduction 
Cancer is one of the leading causes of death and in 2008 the cancer mortality was 
close to 7.6 million deaths worldwide (1). The 5-year cancer prevalence for the adult 
population only was 28.8 million worldwide the same year (2), while the number of 
people diagnosed with cancer in Norway was 27520 in 2009 (3). 
1.1 Cancer as a Genetic Disease 
Cancer is a genetic disease caused by either inherited mutations in genes that control 
genome integrity or by mutations that are acquired in somatic cells during the 
development of a tumor (4), often in response to aging, lifestyle or- environmental 
exposure. Several types of DNA changes can arise and facilitate the change of a 
normal cell to a tumor cell, such as mutations in single nucleotides as well as 
alterations in small stretches of DNA, whole genes, structural components of 
chromosomes or complete chromosomes (4). In addition, epigenetic changes not 
directly altering the DNA sequence are also involved in cancer development (5).  
Two major groups of genes are repeatedly altered in human tumors (6). Genes of the 
first group are called proto- oncogenes and activating mutations in these genes lead to 
an overactive or over expressed form which can result in cancer development (6). 
Genes of the second group are called tumor suppressor genes and inactivating 
mutations in these genes lead to elimination of the gene and can promote cell 
transformation (6).  
1.1.1 Cancer development and progression  
Although there are several different types of cancer, they all have in common that 
genetic and epigenetic changes allow them to escape the normal regulatory machinery 
of the cell resulting in uncontrolled growth and proliferation (6). Cancer is a 
polygenic disorder, meaning that mutations in several genes are required for cancer to 
develop (4). Two of the models explaining tumor evolution are the clonal evolution 
model and the cancer stem cell model (7). In the clonal evolution model a cell 
acquires alterations which gives it a selective advantage (6). When this cell grows and 
divides its descendants may gain a substantial number of favorable genetic and 
epigenetic alterations which can lead to clonal expansion and formation of a tumor 
(6). In this model, all clones have the capacity to undergo proliferation and Darwinian 
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selection (7). In contrast, the cancer stem cell hypothesis is based on a cancer stem 
cell precursor which can both be self-renewing and also give rise to a progeny of 
differentiated cancer cells (7). This model suggests that only the cancer stem cells 
have the potential of self-renewal and can drive tumor progression (7).  
Cancer development is divided into several stages (6). Cells that have obtained 
favorable mutations or epigenetic changes give rise to a benign tumor which is non-
invasive (6). Some benign tumor develops into malignant tumors which contains 
cancer cells that have gain the ability to break through the basement membrane and 
invade the surrounding tissue (6). These cells can enter the bloodstream or lymphatic 
vessels and form secondary tumors in a process called metastasis (6).  
1.1.2 Hallmarks of cancer  
During cancer evolvement the cell acquires several capabilities to become 
tumorigenic and ultimately malignant which are often referred to as the “Hallmarks of 
cancer”(8). Hanahan and Weinberg proposed in 2000 six physiologic changes that a 
cell has to obtain in order to become malignant (Figure 1) (9). These hallmarks 
included sustaining proliferative signaling, evading growth suppressors, resisting cell 
death, enabling replicative immortality, inducing angiogenesis and activating invasion 
and metastasis (9). The authors argued that these acquired hallmarks enhance cell 
proliferation and decrease cell death, make the cells able to receive nutrients and 
oxygen by the formation of new blood vessels and eventually give the cells metastatic 
capabilities necessary for the establishment of new colonies at a distant site in the 
body.  
Eleven years later Hanahan and Weinberg published a follow up article where two 
new emerging hallmarks were presented, deregulating cellular energetics and 
avoiding immune destruction (Figure 1) (8). They proposed that by modifying or 
reprogramming cellular metabolism the cells can use glycolytic intermediates in 
biosynthetic pathways to generate nucleosides, amino acids, macromolecules and 
organelles required for active growth and proliferation (8). In addition, the authors 
suggested that evading immune recognition and suppressing immune reactivity also 
play an important role in the development and progression of many human cancers 
(8). 
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Two enabling characteristics required for the all the eight hallmarks to evolve was 
also implicated by Hanahan and Weinberg (Figure 1) (8). These included genome 
instability and mutation and tumor-promoting inflammation (8).  The authors 
suggested that accumulation of mutations or epigenetic alterations can generate 
genotypes contributing to the acquisition of the hallmark capabilities. In addition, it 
was proposed that inflammatory cells of the tumor microenvironment can supply 
several bioactive molecules to the tumor facilitating angiogenesis, invasion and 
metastasis (8).   
 
Figure 1. Hallmarks of cancer. 
The essential characteristics that 
enable tumor growth and 
metastatic dissemination 
proposed by Hanahan and 
Weinberg are six acquired 
capabilities (1-6), two enabling 
characteristics (7-8) and two 
emerging hallmarks (9-10) (8) 
(Figure modified from (8)).      
 
 
1.1.3 The tumor microenviroment  
The tumor microenvironment has been implicated in cancer progression (8). The 
microenvironment is composed of a diversity of cell types, such as vascular 
endothelial cells, adipocytes, fibroblasts, macrophages and immune cells among 
others, which is suggested to interact with tumor cells via growth factor and cytokine 
networks and promote tumor cell invasion and metastasis (10). Several studies have 
indicated that the tumor microenvironment undergoes extensive changes during the 
evolution and progression of cancers. The interactions between the cells of the 
stromal tissue and the cancer cells are bidirectional and dynamic (11). Cancer cells 
recruit and activate stromal cell types such as tumor-associated fibroblasts, 
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macrophages, leucocytes and mast cells which in turn secrete signalling molecules 
promoting progression of the tumor (11).  
1.2 Breast Cancer  
Breast cancer is the most frequent cancer type among women, and in 2008 1.38 
million women were diagnosed with breast cancer worldwide (2). In Norway the 
number of newly diagnosed cases each year is more than 2700 (3). As a consequence 
of better diagnostics and treatment the 5-year relative survival is increasing and 
between 2005-09 more than 88 percent of women diagnosed with breast cancer 
survived 5 years (all stages combined) (3). Still, the number of breast cancer deaths in 
Norway was the second highest among cancer deaths affecting women in 2009 (3).  
1.2.1 Breast biology and development 
The mammary gland is a complex organ consisting of several different cell-and tissue 
types (Figure 2). The two main components of the human breast are the stroma and 
the parenchyma. The parenchyma is the functional system of branching ducts and 
secretory lobules, while stroma is the supporting adipose tissue, fibroblasts, blood 
vessels and lymphatic vessels that surrounds the ducts and the lobules (12). The 
lobules of the parenchyma consist of secretory epithelial cells that synthesize milk, 
and from each lobule large milk ducts transport the milk produced in the lobules to  
the nipple (13). The lobules and ducts consist of a bi-layer of luminal epithelial cells 
and myoepithelial cells. The luminal epithelial cells are covering the surface of the 
milk ducts and are thus lining the central lumen, while the underlying myoepithelial 
cells are located adjacent to the basement membrane which functions as a physical 
barrier preventing cells from invading the surrounding tissue (Figure 2, lower section) 
(14). The arteries, veins and the lymphatic system of the stroma are responsible for 
the transportation of blood and nutrients to the breast and the exportation of waste 
products. 
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Figure 2. Anatomy of the breast. Above: The major 
components of the human breast are the ducts (A), the lobules 
(B), the dilated section of duct to hold milk (C), the nipple 
(D), fat (E), pectoralis major muscle (F) and chest wall/rib 
cage (G). Below: An cross section of a normal duct showing a 
monolayer of epithelial cells (1), surrounded by the basement 
membrane at the external side (2) and the lumen which is the 
center of the duct (3) at the interior (Figure modified from 
(15)).  
 
 
Hormones play an important role in normal breast development. Between birth and 
puberty, the development of the mammary gland is relatively dormant. However, 
during puberty there is a rapid expansion of the mammary epithelium which generates 
an extensive ductal network driven among others by the steroid hormones estrogen 
and progesterone (16). Throughout life the breast is continuously undergoing changes. 
During the menstrual cycle there is a fluctuation of hormones and proliferation 
followed by apoptosis of the epithelial cells (17). And during pregnancy, a large 
number of milk protein- and lipid secreting luminal cells are developed in addition to 
further ductal branching and infiltration of the stroma (17;18).  
1.2.2 Breast cancer initiation and progression 
Breast tumors have different histopathological appearance depending on the origin of 
the tumor and if it has penetrated the basement membrane or not. Invasive breast 
carcinomas are the most common tumors of the female breast and consist of a group 
of malignant epithelial tumors. The majority of these tumors are adenocarcinomas 
derived from the parenchymal epithelium of the mammary gland (19). Invasive ductal 
carcinoma (IDC) and invasive lobular carcinoma (ILC) are the two major histological 
types of invasive breast carcinomas, constitute approximately 80% and 10-15% of all 
invasive breast cancers, respectively (20). Ductal carcinoma in situ (DCIS) which is 
considered an precursor of IDC consists of cells that have not penetrated the basement 
membrane and accounts for about 20-25% of newly diagnosed cases (21).    
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Breast cancer originates when a normal epithelial cell of the breast acquires genetic 
and epigenetic alterations, and tumor progression is driven by further accumulations 
of these abnormalities (22). Telomere shortening leading to genomic instability (23) 
and microenviromental alterations (22) are other drivers of tumorigenisis. Breast 
cancer progression of ductal carcinomas is a multistep process (Figure 3) starting with 
atypical ductal hyperplasia (ADH) which is a premalignant lesion of abnormal 
epithelial cells within the duct. Next, ductal carcinoma in situ (DCIS) evolves when 
the basement membrane is degraded and the carcinoma becomes invasive. The cells 
can then escape the primary site and infiltrate the surrounding tissue. Metastatic 
carcinomas arises when the cells of the invasive carcinoma have established a new 
tumor at a distant site (14).       
 
Figure 3. Schematic outline of ductal breast tumor progression. In normal breast ducts or lobules the 
basement membrane encapsulates the bi-layer of epithelial and myoepithelial cells. In ductal carcinoma 
in situ the epithelial cells have increased extensively in number due to increased proliferation. 
Degradation of the basement membrane result in invasive carcinoma, and the cells can escape the 
primary site. Metastatic carcinoma arises when cancer cells from the invasive carcinoma enter  the 
vasculature of the primary stroma and seed secondary tumors in a foreign microenviroment (7).  
This traditional model explains breast cancer progression in a linear, step-wise 
fashion. However, it has been indicated that this model is overly simplistic (24). Thus, 
several different models explaining breast cancer progression have been proposed and 
will be discussed later in the context of intratumor heterogeneity (see chapter 1.4.1).   
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1.2.3 Risk factors  
Both hereditary and environmental risk factors are involved in the probability of 
developing breast cancer. Familial breast cancer constitutes about 5-10% of all breast 
cancer cases, while the remaining are classified as sporadic breast cancer (Figure 4). 
Germline mutations in high-penetrance cancer susceptibility genes, including the 
double-strand DNA break repair genes BRCA1 and BRCA2, account for about 16% of 
the risk of developing familial breast cancer (Figure 4) (25). The remaining familial 
risk may be due to genetic or environmental factors. However, studies have indicated 
that inherited genetic factors predominate the excess familial risk (26). Mutations in 
several other breast cancer susceptibility genes, including TP53, PTEN and ATM, 
have been implicated to account for a smaller proportion of the familial risk (Figure 4) 
(27;28).  
Figure 4. Familial and sporadic breast cancer. Familial breast cancer constitutes only 5-10% of total 
breast cancer (right panel). BRCA1 and BRCA2 are high-penetrance breast cancer susceptibility genes, 
and mutations in these genes account for about 20% of the familial risk (left panel). Most of the genetic 
variants that contribute to the risk of developing sporadic breast cancer are unknown (4).  
The majority of all breast cancers are sporadic resulting from acquisition of numerous 
somatic mutations. However, most of the somatic mutations leading to sporadic breast 
cancer are unknown (4). Genome-wide association studies (GWAS) have identified a 
number of new genetic variants such as single nucleotide polymorphisms (SNPs) 
influencing breast cancer risk (Figure 5) (29). SNPs are inherited genomic variations 
in the DNA sequence and the most frequent type of variation in the human genome 
(30). SNPs occur when a single nucleotide at a specific locus in the genome differs 
between individuals in a population or between populations. The variation in a single 
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nucleotide has to be above 1 % in frequency in the population to be called a SNP. 
DNA variations at lower frequencies are known as rare variants or mutations (31).  
 
Figure 5. Genetic risk factors including breast cancer susceptibility loci and genes. All known breast 
cancer susceptibility genes are shown between the red and blue line. High-risk genes are highlighted in 
green, moderate-penetrance genes are highlighted in red while the low-risk genes are shown in orange 
(32).  
A number of environmental and lifestyle breast cancer risk factors have been 
identified. Age, exposure to the hormone estrogen, diet, alcohol consumption and 
exposure to ionising radiation have all been implicated to increase the risk of 
developing breast cancer (33). Early onset of menarche, late menopause, late age at 
first full-term pregnancy and obesity influence the estrogen exposure and are 
therefore contributing factors to breast cancer risk (33). In addition, exogenous 
estrogen exposure such as oral contraceptives and hormone replacement therapy also 
increase the risk of breast cancer development although only transiently (33).         
1.3 Breast Tumor Classification  
Breast cancer is a highly heterogeneous disease considering the diversity in genetic 
and genomic variations, histopathological features and patient outcomes (14). Breast 
tumors can be classified by a number of approaches into distinct groups in order to 
assess the most favourable treatment regime or likely outcome for each patient. Both 
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prognostic markers that provide information regarding patient outcome and predictive 
markers that give information about response to a given drug or treatment are 
identified by tumor classification (34). Guidelines from World Health Organization 
classify breast cancer into several clinical categories based on histological tumor type, 
histological grade, tumor stage, expression of estrogen receptor alpha (ER) and the 
progesterone receptor (PR) and over expression of the human epidermal growth factor 
receptor 2 (HER2) (19). Here, the traditional clinical features for breast tumor 
classification will be described.  
1.3.1 Histological grade 
Histological grading of breast cancer is based on the differentiation of the tumor 
tissue (35). Three morphological features, which includes nuclear pleomorphism 
(changes in size, shape and color), mitotic count (the proportion of dividing cells) and 
to what extent the tumor has formed tubules, are evaluated during the grading (36). 
Together these three features are translated into a tumor grade raging from 1-3. Grade 
1 corresponds to a well-differentiated tumor with high homology to normal breast 
tissue, showing a mild degree of cellular pleomorphism and low mitotic count. Grade 
2 corresponds to a moderately differentiated tumor, and grade 3 to a poorly 
differentiated tumor with a high degree of nuclear atypia, frequent mitosis and no 
tubule formation (35). Histological grade has been shown to have a prognostic value, 
patients with grade 1 tumors have markedly better survival than those with grade 2 
and 3 tumors (37).  
1.3.2 Tumor stage 
Breast tumor staging is based on the international standard tumor-node-metastasis 
(TNM) staging system (38). In the TNM staging system three features of the primary 
tumor, tumor size (T), regional lymph node status (N) and the presence of distant 
metastasis (M), are evaluated (39). Tumor size (T) is divided into four categories, 
where T1 includes tumors that are smaller or equal to 2 cm, T2 compromises tumors 
between 2 and 5 cm, T3 consist of tumors greater than 5 cm and T4 includes tumors 
which have extended into either the chest wall or to the skin. Regional lymph node 
status (N) is raging from N0-N3 and categorizes tumors according to the number and 
location of positive regional lymph nodes. Distant metastasis (M) reflects whether or 
not the primary tumor has metastasized to distant sites. The three TNM parameters are 
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combined in a TNM stage grouping system which classifies breast tumors into four 
stages (Table 1) (39). The distinct stages show prognostic differences, the relative 
survival is decreasing with increasing tumor stage (40). 
Table 1. TNM classification of breast tumors. Stage 0 consists of carcinoma in situ tumors with 
negative node status and no distant metastasis. Stage 1 includes small (T1) and localized tumors. Stage 
2 consists of tumors with different sizes (T0-T3), different nodal involvement (N0-N1) and no distant 
metastasis. Stage 3 includes either tumors of different size (T0-T3) with many positive lymph nodes 
(N1-N2) or tumors that have extended the chest wall or skin (T4) with various lymph node status (N0-
N2) and no distant metastasis. Stage 4 comprises tumors of any size and lymph node status that have 
metastasized to distant organs (39). 
 
1.3.3 Receptor status 
Evaluation of the two hormone receptors estrogen receptor (ER) and progesterone 
receptor (PR) in addition to the human epidermal growth factor receptor 2 (HER2) are 
routinely used as prognostic and predictive markers for management of breast tumors 
(41). ER and PR are both members of the nuclear hormone receptor family, and are 
stimulated by the estrogen and progesterone hormone, respectively (16). Estrogen is 
the main hormone that controls breast cancer proliferation by interacting through ER 
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(42). Expression of the two hormone receptors are assessed by immunohistochemistry 
(IHC) which measure the protein expression of ER and PR. ER status is critical for 
the identification of breast cancer patients that may benefit from anti-estrogen 
(endocrine) therapy such as ER antagonists (e.g. tamoxifen) or aromatase inhibitors 
(43;44). PR status is generally correlated with ER status, however the presence of this 
hormone receptor has less clinical significance (45). Considering the prognostic value 
of hormone receptor status, breast cancer patients with ER+ and/or PR+ tumors show 
the best overall outcome (46).  
The HER2 receptor tyrosine kinase is a member of a family of transmembrane growth 
factor receptors that are involved in regulating normal cell proliferation and survival. 
The receptor is over expressed in approximately 20% of all breast tumors (47). HER2 
is a marker for poor prognosis with a decreased overall survival (48;49). The level of 
HER2 protein expression is evaluated by IHC while HER2 gene amplification is 
assessed by fluorescence in situ hybridization (FISH) (41). HER2+ breast tumors can 
be treated with targeted therapy such as the monoclonal antibody trastuzumab, and 
treatment with such therapies has improved the overall outcome for patients in this 
group (50;51). Combination of the ER, PR and HER2 receptor status allow for the 
classification of breast tumors into different categories with distinct prognosis. Triple 
negative tumors (ER-/PR-/HER2-) are associated with the worst prognosis (52).  
1.4 Molecular Subtypes of Breast Cancer  
Breast cancer is no longer believed to be a single disease, but rather heterogenous 
both at the clinical and the molecular level (7). The heterogeneity of breast tumors is 
both intratumoral and intertumoral. Intratumor heterogeneity is the variation within a 
single tumor. In contrast, intertumor heterogeneity is variation between tumors from 
different patients (34). These variations can be captured by a diversity of methods in 
molecular biology and molecular genetics and used to classify the tumors into 
molecular subgroups. The subgroups may have different risk factors, clinical 
presentation, histopathological features, outcome and response to therapy (53). The 
aim behind molecular classification of breast cancer is to individualize the diagnosis 
and treatment of breast cancer and better predict the clinical outcome for patients in 
each subgroup (34;53).  
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1.4.1 Intratumor heterogeneity  
As mentioned above, two proposed models explaining tumor progression are the 
clonal evolution and the cancer stem cell model (22). However, new insights into 
breast cancer progression have led to several proposed models aiming to explain the 
progression of breast tumors and also to explain the appearance of subpopulations 
within tumors (Figure 6) (24). The clonal evolution and the cancer stem cell models 
have both been proposed as linear models giving rise to monogenomic tumors, and 
also as diversity models giving rise to polygenomic tumors where multiple clones 
reside within the tumor (34). In addition, a separate mutator phenotype model in 
which tumors evolve by gradual and random accumulations of mutations as the tumor 
grows are also proposed and give rise to highly diverse tumors (34).  
 
Figure 6. Three hypothetical models explaining intratumor heterogeneity. The clonal evolution (A), the 
cancer stem cell (B) and the mutator phenotype (C) models are different cancer progression models 
explaining how distinct types of intratumor heterogeneity arise. Different subpopulations of tumors (D) 
can be a result of the different models of tumor  progression  (34). 
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1.4.2 Intertumor heterogeneity  
Gene expression studies have identified several distinct breast cancer subtypes. Perou 
and Sørlie classified breast cancer tumors into five subtypes based on their gene 
expression profile. They performed hierarchical clustering by using breast cancer 
specimens and a subset of genes they termed the ‘intrinsic’ gene set. These genes 
were found to be more differentially expressed between tumors from different 
patients, than between tumor samples from the same individual sampled twice. Based 
on the gene expression profiles they observed after the clustering analysis, the tumors 
were divided into five subtypes which included luminal A, luminal B, ERBB2+ (later 
designated HER2-enriched), basal-like and normal-like tumors (Figure 7) (54;55).  
Figure 7. Breast cancer molecular subtypes classified by gene expression profile. Five distinct breast 
cancer subtypes were identified by Perou and Sørlie on the basis of their gene expression patterns. The 
molecular subtypes compromised luminal A (purple), luminal B (light blue), HER2-enriched (pink), 
basal-like (red) and normal-breast like (green) (Figure modified from (56)).  
Luminal A and B subtypes are mostly ER positive and express many genes 
characteristic for breast luminal epithelial cells (55). Luminal A tumors are strongly 
ER positive and are also characterized as being HER2 negative, have low expression 
of proliferation associated genes such as Ki-67 and TP53 tend to be wild-type (57).  
The Luminal B subtype is weak or moderate ER positive, HER2 positive, has higher 
proliferation signature and mutated TP53 (57). In contrast to the luminal subclasses, 
the other three subtypes are characterized by low or absent expression of ER. The 
HER2-enriched subtype has high expression of several genes in the HER2 amplicon, 
while the basal-like tumors are often ER, PR and HER2 negative which is clinically 
referred to as triple negative tumors. The normal breast-like tumors express genes 
associated with normal breast tissue, they show strong expression of basal epithelial 
cells and low expression of luminal epithelial cells (54;55). Recent studies have 
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identified a new breast cancer intrinsic subtype called claudin-low which is 
characterized by mesenchymal and stem cell features (58).     
Several models explaining the intertumoral heterogeneity of breast cancers have been 
proposed, suggesting that the intrinsic subtypes may arise from different cells of 
origin and have various progression pathways (7). Two of these models are the ‘cell 
of origin’- and ‘tumor subtype-specific transforming event’ models (Figure 8) (7). In 
the ‘cell of origin’ model each tumor subtype is initiated in a different cell type. While 
in the ‘tumor subtype-specific transforming event’ model the cell of origin can be the 
same for all the different subtypes, but specific genetic and epigenetic events give rise 
to the distinct molecular subtypes (7).  
Figure 8. Two hypothesized models explaining the development of the distinct breast cancer intrinsic 
subtypes. Different cell types give rise to the distinct tumor subtypes in the ‘cell of origin’ model (A). 
In contrast, the same cell gives rise to the subtypes in the ‘tumor subtype-specific transforming event’ 
model. In the latter model both mutations and epigenetic changes are involved in the generation of the 
different subtypes (B).  
Perou and Sørlie showed that the classification of breast cancer tumors based on gene 
expression patterns has clinical implications, and this have been validated by other 
studies. The subgroups display differences in overall and relapse-free survival (55). In 
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particular, basal-like, HER2-enriched and luminal B subtypes have the worst 
prognosis compared to the luminal A subtype which show the most favourable 
outcome (55).  
The discovery of variations in gene expression between the molecular subtypes of 
breast cancer has lead to the development of commercial diagnostic tests to determine 
prognosis and predict response to treatment (59). MammaPrint DX was the first 
prognostic signature approved by the FDA (US Food and Drug Administration) and is 
a microarray-based test that measures the gene expression of 70 genes (60). The assay 
is designed to predict the clinical outcome of breast cancer patients (development of 
distant metastasis within 5 years) and in addition to give a predictive value for 
chemotherapy response (61). Oncotype DX is another prognostic signature that 
estimates the expression level of 21 genes by qRT-PCR. The assay predicts the risk of 
distant relapse at 10 years by a recurrence score (62) in addition to predict the 
chemotherapy response for patients in each risk group (59).  
1.5 Breast Cancer Treatment  
Treatment options for breast cancer are based on characteristics of the patient as well 
as characteristics of the tumor (63). The treatment of breast cancer includes surgery, 
radiotherapy, chemotherapy, endocrine therapy and targeted therapy (63). In Norway, 
treatment for breast cancer patients is standardized nationally and follows the 
guidelines to the Norwegian Breast Cancer Group (NBCG) (63). Patient information 
such as age and genetic predisposition are evaluated to tailor the treatment. 
Information regarding tumor size, histological stage and grade, ER, PR and HER2 
receptor status and expression of the proliferation associated gene Ki-67 are used in 
the decision making regarding therapy regime.  
1.5.1 Chemotherapy  
Systemic treatment, such as chemotherapy, is traditionally administered after the 
tumor is surgically removed (adjuvant) to reduce the risk of recurrence and to increase 
the overall survival (64). In addition, it can also be administered neoadjuvant (before 
surgery) for instance to decrease the tumor volume pre-operatively (65). The principle 
behind chemotherapeutics is that they target rapidly dividing cells by interrupting cell 
division, thereby killing the fast growing cancer cells. Several cancer 
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chemotherapeutic drugs induce excessive DNA damage resulting in cell-cycle arrest 
and cell death. However, the distinct chemotherapeutic agents have different 
mechanism of action (66). Although chemotherapeutics target the rapidly diving 
cancer cells, many therapies fail to remove all cancer cells increasing the change of 
relapses. Why some cells in the tumor escape the treatment have led to several 
proposed theories, such as the cancer stem-cell hypothesis (67). It have been 
suggested that genetic variation in certain clones in the tumor may provide the 
opportunity of some cells to escape therapy. In addition, other non-genetic 
mechanisms such as epigenetic changes have been implicated to be involved in the 
selection by therapy (68).  
1.5.2 Doxorubicin 
The patients included in this thesis have received neoadjuvant treatment with 
doxorubicin (Figure 9). Doxorubicin is a member of the anthracycline family of 
antibiotic chemotherapeutic agents which are considered some of the most effective 
anti-cancer agents used for cancer therapy (69). Doxorubicin is the most widely 
administered anthracycline antibiotic and is used for the treatment of solid tumors 
(70;71).  
 
Figure 9. The chemical structure of doxorubicin. Doxorubicin is a antineoplastic antibiotic obtained 
from Streptomyces peucetius belonging to the anthracycline family of chemotherapeutics (72). 
Numerous mechanisms responsible for the cytotoxic actions of doxorubicin have been 
proposed, and the different mechanisms have been subjected to substantial debate 
(71). However, the primary mechanism of action is thought to be the inhibition of 
topoisomerase II by the stabilization of the topoisomerase II-DNA complex (Figure 
10). Topoisomerase II induces transient DNA breaks during DNA replication and 
other cellular processes to relax supercoiled DNA or to allow DNA strands to pass 
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through each other (73). When topoisomerase inhibitors are used as cancer treatment, 
processes such as DNA replication, transcription and repair which require changes in 
DNA topology are therefore interfered. The formation of double-strand DNA breaks 
promoted by this action leads to cell death (71;74). In addition to topoisomerase-
inhibition, other mechanism including DNA intercalation, free radical formation and 
helicase inhibition have also been suggested to be involved in the anti-cancer actions 
of doxorubicin (71;74).     
 
Figure 10. Doxorubicin pathway in cancer cells. Doxorubicin is transported into the cell and has 
several proposed mechanism of action, such as inhibition of the topoisomerase II-DNA intermediate 
leading to double strand breaks and generation of free radicals leading to DNA and cell membrane 
damage. Doxorubicin action leads ultimately to cell death which gives it an antitumor activity (75). 
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Cardiotoxicity and cellular resistance are the most important limitations of the clinical 
use of doxorubicin (69). Acute and chronic irreversible cardiotoxicity are the major 
adverse effect of doxorubicin therapy. Several mechanism have been implicated in the 
myocardial damage that may lead to congestive heart failure induced by doxorubicin 
(76).  The mechanisms of cellular resistance to doxorubicin are thought to be different 
from those of the mechanisms of cardiotoxicity. Mechanisms behind resistance have 
been proposed to involve among other drug efflux mediated by membrane 
transporters such as ABCB1 and ABCG2 leading to decreased intracellular 
concentrations of doxorubicin (77). Mutations in the tumor suppressor protein p53, 
which trigger cell-cycle arrest and apoptosis in response to cellular stress signals, 
have also been reported to be involved in resistance to doxorubicin (78). 
Interindividual variation between patients in doxorubicin pharmacology including 
efficacy and toxicity have been hypothesized to be a result of genetic variation (70).  
Increased information regarding the mechanisms of doxorubicin in addition to 
identification of clinical predictive biomarkers may be important to assess those 
patients that will benefit from doxorubicin therapy and those that will not. Since 
doxorubicin treatment can lead to cardiotoxicity in addition to the common side 
effects of chemotherapeutics such as nausea and hair loss, identification of the 
patients that will not benefit from the treatment regime will spear them from these 
unfortunate side effects. The same is true for the patients that develop 
chemoresistance to doxorubicin. This evaluation may lead to administration of “right 
drug to the right patient”, which is one of the overall goals in cancer research.       
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2. Aim of the Study 
In this study tumor specimens collected from breast cancer patients before and after 
neoadjuvant treatment (before surgery) with doxorubicin were analyzed. As described 
above doxorubicin is an anticancer anthracycline, which primary mechanism of action 
appears to be the inhibition of topoisomerase II in transient cleavage complex with 
DNA. However, the pathways underlying doxorubicin effect on tumor cells are not 
well understood. The overall aim in this study is to further increase our knowledge of 
the pathways underlying doxorubicin effect on tumor cells and to elucidate the 
mechanism of patients response to doxorubicin treatment, by using whole genome 
mRNA analysis to assess mRNA expression levels in tumor tissue before and after 
doxorubicin treatment. In addition, p53 has been proposed to modulate topoisomerase 
activity and it has been suggested that tumor cells with mutated p53 have an 
abnormally activated topoisomerase which may contribute to the genetic instability in 
tumors. Certain p53 mutations have also been connected to doxorubicin resistance. 
The gene expression pattern in tumor samples with mutated compared to wild type 
p53 was therefore examined. Some of the tumor samples included in this study have 
previously been classified using early cDNA microarrays containing only 8102 
human genes. By utilizing mRNA arrays with a larger amount of probes and higher 
resolution this study also aimed to compare the previous classification with 
information from new microarrays. 
More specifically, the aims in this study are to investigate: 
1. The alterations in gene expression following treatment both at the individual 
gene level as well as pathway based  
2. The association between mRNA expression profiles and response to therapy 
both at the individual gene level as well as pathway based  
3. The association between mRNA expression profiles and TP53 mutation status 
in the tumor samples 
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The main focus will be on the following topics: 
- Is the gene expression profile in tumor tissue changed as a result of 
doxorubicin therapy? If so, which genes and pathways are implicated? 
- Can changes in mRNA expression profile be connected to differences in 
response to doxorubicin treatment?  
- Is the gene expression profile different between patients that have a mutated 
p53 compared to those that have wild type p53? 
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3. Material 
The material included in this thesis was collected previously for other studies. The 
tumor samples were analyzed and included in a study of breast tumor classification 
based on mRNA expression profile using early generation cDNA expression arrays 
with a limited number of probes (54) in addition to a study examining the effect of 
TP53 mutations on resistance to doxorubicin treatment (78).   
3.1 Patient Material and Therapy Regime   
The material in this thesis consists of tumor biopsies collected from breast cancer 
patients with locally advanced breast cancer (stage 3 and 4). The patients were 
between 32 and 88 years of age, with a median age of 64 years. The majority of the 
tumors were invasive ductal carcinomas, but some were also lobular carcinomas and 
tumors classified as other histological types. The tumors were graded according to the 
three morphological features explained in chapter 1.3.1. A total of 128 tumor 
specimens collected from 72 patients were included in this study. 56 of the tumors 
were sampled twice from the same patient, before and after doxorubicin monotherapy 
(14 mg/m
2
) for an average of 16 weeks (range 12-23). The ‘before’ samples were 
collected prior to therapy by an open biopsy, while the ‘after’ samples were collected 
during surgery. In addition to the 56 before and after pairs collected from the same 
tumor, 16 ‘single’ samples were included in this study. These samples included eight 
samples collected before therapy and eight samples collected after therapy from 
different patients. In all, the 128 samples compromised 64 before and 64 after 
samples. RNA from these samples was extracted using Trizol and RNeasy minikit 
from Qiagen. 
The patients originally included in the previous studies were assessed with clinical 
response, according to the Union International Contre Cancer criteria, based on the 
alterations in tumor size after neoadjuvant doxorubicin therapy (79). Patients were 
categorized into the responses groups complete response (CR), partial response (PR), 
progressive disease (PD), stable disease and (SD) and minimal change (MC).  The 
complete responders had disappearance of all tumor lesions while the partial 
responders had reduction ≥50% in the sum of all lesions. In contrast, the patients 
assessed with progressive disease had an increase in the diameter product of any 
individual tumor lesion by ≥25%, indicating a lack of sensitivity to treatment. Patients 
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characterized with stable disease and/or minimal change had a response between PR 
and PD i.e. reduction <50 % of all tumor lesions or increase in the diameter product 
of any individual tumor lesion by <25 %. The 72 patients included in this study were 
only assessed with partial response, stable disease and minimal change. The patients 
assessed with partial response were characterized as doxorubicin responders, while 
the patients assessed with stable disease and/or minimal change were characterized as 
non-responders to doxorubicin.   
3.2 Clinical Data  
Clinical and histopathological parameters including ER status, grade and p53 status 
were available for all the 128 tumor samples included in this study. The patients, 
which these tumor samples were collected from, were grouped according to if they 
obtained partial response (PR) or stable disease and/or minimal change (SD/MC) to 
doxorubicin treatment. The distribution of patients in the two response categories in 
addition to the clinical-histopatological parameters of the tumor samples are listed in 
Table 2. Survival data, tumor size, lymph node status and data on distant metastasis 
were also available but were not included in the analyses in this thesis.  
Table 2. Patient characteristics. Clinical-histopatological parameters such as ER status, grade and p53 
status in addition to data on response for the patients (n=128) included in this thesis. The numbers of 
patients in each category, in addition to the percentage are displayed.  
 
 
 
 
Characteristics  No. of patients % 
ER positive 108 84.4 
ER negative 20 15.6 
Tumor grade 1 35 27.4 
Tumor grade 2 62 48.4 
Tumor grade 3 31 24.2 
p53 wild type 99 77.3 
p53 mutated 29 22.7 
Partial response 55 43 
Stable disease/minimal change 73 57 
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4. Methods 
In this section, the different laboratory-and statistical methods used in this project are 
described. A table with all the reagents and equipment used are listed in Appendix A.  
4.1 Microarray Technology 
Microarray technology is utilized in a number of genetic experiments to analyze 
among other DNA sequence variation such as single nucleotide polymorphism (SNP), 
mRNA expression, miRNA expression, DNA methylation and protein expression. 
Genome-wide microarrays have made it possible to make the analysis globally. The 
principle behind this technology (Figure 11) is to immobilize probes that are 
complementary to the molecules of interest (e.g. DNA or RNA) on a surface. The 
sample molecules are labeled with substances that emit signals (e.g. fluorescence) 
followed by hybridization to the complementary probes on the array. After 
hybridization the array is scanned and the signals from the samples are measured. The 
data generated is then normalized to make the signals comparable to reveal biological 
differences (80). A number of different microarray platforms exist and they vary 
among other in genomic coverage, probe type, probe number, probe immobilization, 
sample hybridization and sample labeling (81).  
Figure 11. Schematized experimental process using microarray technology. The standard workflow for 
all microarray platforms measuring gene expression includes isolation of RNA or mRNA from 
biological specimens, generation and labeling of complementary DNA (cDNA) or complementary 
RNA (cRNA), hybridization to a microarray, washing of unhybridized samples and final scanning of 
the microarray under laser light (80).  
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4.2 Whole-Genome mRNA Array 
The whole-genome mRNA analysis was performed according to the One-Color 
Microarray-Based Gene Expression Analysis Protocol from Agilent Technologies 
(Version 6.5, May 2010) using the Human GE 4x44K Microarray. This is a nucleic 
acid microarray which utilizes oligonucleotides as array elements that are attached to 
solid surfaces. The one-channel array provides intensity for each probe indicating a 
relative level of hybridization. The high throughput genome-wide array measures 
gene expression in experimental and control samples by the use of cyanine 31 (Cy3)-
labeled targets (82). The procedure includes sample preparation which converts 
mRNA to cDNA and further to Cy3-labeled cRNA, hybridization to 60-mer 
oligonucleotide probes, microarray wash and final scanning and feature extraction 
(Figure 12) (82).  
Figure 12. The standard workflow for sample preparation and array processing.  Total RNA and Spike-
In RNA are prepared, and the labeled cRNA generated are purified before it is hybridized to 
microarrays containing oligonucleotide probes. The arrays are then washed before scanning and feature 
extraction (82).  
The Agilent One-Color Spike-In controls are required for use with the Agilent One-
Color gene expression microarray workflow because gene expression microarray 
                                                          
1
 Cyanine 3 is a synthetic fluorescent dye which is used in microarray experiments for nucleic acid 
labeling.  
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experiments are multi-step procedures and many parameters may influence the 
microarray data (83). The positive controls consist of 10 in vitro synthesized, 
polyadenylated transcripts derived from the Adenovirus E1A gene which are labeled 
and amplified together with the experimental samples (83). The controls are 
optimized to anneal to complementary probes on the microarray, and after the 
hybridization the signal intensities for each control transcript can be used to monitor 
the microarray workflow from sample amplification and labeling to microarray 
processing performed in the experiment (83). 
4.2.1 Sample preparation 
In this step cDNA is synthesized from mRNA samples followed by the synthesis of 
fluorescent labeled cRNA (Figure 13) (82). The sample preparation process includes 
preparation of the one-color spike mix, preparation of the labeling reaction and the 
labeling reaction itself, purification of the labeled and amplified RNA and 
quantification of the cRNA (82).  
In the labeling reaction cDNA is generated that carries a T7 promoter primer at its 
5’end by using among other T7 Promoter Primer and AffinityScript Reverse 
Transcriptase (82). The double-stranded cDNA serves as a template for a process in 
which T7 RNA polymerase amplifies target material and simultaneously incorporates 
Cy3-labeled nucleotides (CTP) into the cRNA (82). 
The amplified and labeled cRNA are purified using Qiagen’s RNeasy mini spin 
columns and quantified using NanoDrop DN-1000 UV-VIS Spectrophotometer to 
ensure that the amplification is successful. 
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Figure 13. Generation of cRNA for one-color 
microarray experiment. cDNA are first generated that 
carries a T7 promoter at its 5’end, and the cDNA 
serves then as a template for a reaction in which Cy3-
nucleotides are incorporated into the cRNA (82).         
 
 
 
 
 
 
 
 
 
 
4.2.1.1 Procedure  
Preparation of the One-Color Spike Mix: 
1. Agilent One-Color Spike Mix stock solution was heated at 37 °C for 5 minutes 
and serial dilutions were created using Dilution Buffer appropriate for 40 ng of 
total RNA input amount, to make the amount of spike mix proportional to the 
amount of RNA input 
 
Preparation of the labeling reaction: 
Steps: 
1. 2 µl of total RNA was added to 1.5 ml microcentrifuge tubes before 2 µl of 
diluted Spike Mix was added to each tube containing sample  
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2. T7 Promoter Primer Mix was prepared with 4 µl T7 Promoter Primer and 2.5 
µl Nuclease-free water before 1.3 µl of the T7 Promoter Primer Mix was 
added to each tube containing total RNA and diluted Spike Mix 
3. The primer and the template were denaturated by incubating the tubes at 65 °C 
for 10 minutes before the tubes were placed on ice for 5 minutes 
4. 5X First Strand Buffer was prewarmed at 80 °C for 3 to 4 minutes before the 
cDNA Master Mix was prepared with 10 µl 5X First Strand Buffer, 5 µl DTT, 
2.5 µl dNTP mix and 6 µl AffinityScript RNase Block Mix 
5. 4.7 µl of cDNA Master Mix was added to each sample tube before the tubes 
were incubated  at 40 °C for 2 hours followed by incubation at 70 °C for 15 
minutes and then the tubes were placed on ice for 5 minutes 
6. Transcription Master Mix was prepared with 3.75 µl Nuclease-free water, 16 
µl 5X Transcription Buffer,  3 µl DTT, 5 µl NTP mix, 1.05 µl T7 RNA 
Polymerase Blend and 1.2 µl Cy3-CTP 
7. 6 µl of Transcription Master Mix was added to each sample tube before the 
tubes were incubated at 40 °C for 2 hours  
 
Purification of the labeled/amplified RNA: 
Steps: 
1. 84 m µl of nuclease-free water, 350 µl Buffer RLT and 250 µl ethanol (>96%) 
were added to the cRNA samples before 700 µl of the cRNA samples were 
added to RNeasy Mini Spin columns placed in 2 ml collection tubes  
2. The samples were centrifuged at 4 °C for 30 seconds at 13000 rpm, the flow-
through was discarded and 500 µl of buffer RPE (containing ethanol) was 
added to each column 
3. The samples were centrifuged at 4 °C for 30 seconds at 13000 rpm, the flow-
through was discarded and another 500 µl of buffer RPE (containing ethanol) 
was added to each column before the samples were centrifuged 4 °C for 60 
seconds at 13000 rpm 
4. The flow-through was discarded before the samples were centrifuged at 4 °C 
for 30 seconds at 13000 rpm to remove remaining traces of buffer RPE 
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5. The RNeasy columns were transferred to new 1.5 ml collection tubes before 
30 µl nuclease-free water was added to each column to elute the cleaned 
cRNA samples 
6. After 1 minute incubation the samples were centrifuged at 4 °C for 30 seconds 
at 13000 rpm before the collection tubes containing cRNA were placed on ice 
 
Quantification of the cRNA: 
Steps: 
1. The cRNA samples were quantified using NanoDrop ND-1000 UV-VIS 
Spectrophotometer version 3.7.1 (see method chapter 4.4) 
2. Cy3 dye concentration (pmol/µl), RNA absorbance ratio (260 nm/280 nm) and 
cRNA concentration (ng/µl) were recorded 
3. The yield (µg) and specific activity (pmol Cy3 per µg cRNA) of each reaction 
were determined  
 
4.2.2 Hybridization 
Before hybridization RNA samples are first fragmented by a fragmentation buffer to 
optimize the cRNA target size (82). A blocking agent is used to minimize non-
specific binding (82). A hybridization buffer is added to stop the fragmentation 
reaction and  the samples are dispensed onto the Human GE 4x44K v2 microarray 
gasket slide (82). The Human GE 4x44K v2 oligo microarray slide containing 60-mer 
oligonucleotide probes is then placed down onto the gasket slide (82). The 
hybridization is prepared in Agilent microarray hybridization chamber which consists 
of a chamber base, a chamber cover and a clamp assembly (Figure 14) (82). The 
hybridization chamber is incubated in a hybridization oven (G2545A) at 65 °C and 10 
rpm for 17 hours to hybridize the labeled RNA samples to the complementary probes 
on the microarray (82).  
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Figure 14. Agilent microarray hybridization chamber 
assembly. The microarray gasket slide and the oligo 
microarray slide are assembled in a hybridization 
chamber before the chamber is placed in hybridization 
oven to hybridize cRNA to the oligonucleotides on 
the oligo microarray slide (84). 
 
4.2.2.1 Procedure  
Preparation of hybridization samples: 
Steps: 
1. The 10X Blocking Agent was heated at 37 °C for 4 to 5 minutes 
2. Fragmentation mix was made by adding 1.65 µg Cy3-labeled, amplified 
cRNA, 11 µl 10X Blocking Agent, Nuclease-free water (bringing the volume 
up to 52.8 µl) and 2.2 µl 25X Fragmentation Buffer to a 1.5 ml nuclease-free 
microfuge tube 
3. The sample tubes were incubated at 60 °C for 30 minutes to fragment RNA 
before the tubes were placed on ice for 1 minute 
4. 55 µl of 2x HI-RPM Hybridization Buffer was added to each sample tube to 
stop the fragmentation reaction before the tubes were centrifuged for 1 minute 
at room temperature at 13000 rpm and then placed on ice 
 
Preparation of hybridization assembly: 
Steps: 
1. A clean microarray gasket slide was placed into the Agilent microarray 
hybridization chamber base with the barcode facing up before hybridization 
sample was slowly dispensed onto the gasket well 
2. The oligo microarray slide, Human GE 4x44K Microarray, was slowly placed 
in the right orientation down onto the gasket slide before the chamber cover 
was placed onto the sandwiched slides and the clamp assembly was hand-
tighten onto the chamber 
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3. The assembled chamber was vertically rotated to wet the gasket and assess the 
mobility of the bubbles before it was placed in a hybridization oven set to 65 
°C and 10 rpm, and hybridized for 17 hours  
4.2.3 Microarray wash 
After the hybridization step the microarray slides are washed in Gene Expression 
Wash buffer 1 and 2 to remove unhybridized and non-specifically hybridized cRNA 
(82). Triton X-102 is added to the buffers to reduce the possibility of array wash-
related background artifacts (82).  
4.2.3.1 Procedure  
Steps: 
1. 2 ml 10 % Triton X-102 were added to wash buffer 1 and 2 in the cubitainer 
before  Gene Expression Wash Buffer 1 was added to the disassembly dish 
and to the 1
st
 wash dish 
2. A slide rack was placed into the 1st wash dish before a magnetic stir bar was 
added and the dish was placed on a magnetic stir plate 
3. Gene Expression Wash Buffer 2 was added to the 2nd wash dish, the dish was 
placed on a heat plate and a magnetic stir bar was added before the buffer was 
heated to 37 °C 
4. The hybridization chamber was removed from the hybridization oven before 
the chamber was disassembled 
5. The array-gasket sandwich was quickly transferred to the disassembly dish 
containing Gene Expression Wash Buffer 1 before the two slides was 
separated using a forceps 
6. The microarray slide was placed into the slide rack in the 1st wash dish 
containing Gene Expression Wash Buffer 1 at room temperature for 1 minute 
7. The slide rack was transferred to the 2nd wash dish containing Gene 
Expression Wash Buffer 2 at 37 °C for 1 minute before the slide rack was 
slowly removed to minimize droplets on the slides 
8.  A forceps was used to remove the microarray slide from the slide rack and the 
array slide was then placed in a light protected slide holder 
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4.2.4 Scanning and feature extraction  
After the washing of the microarrays the slides are scanned using Agilent C Scanner 
(G2565CA) (82). This is a high-resolution microarray scanner that measures the 
fluorescence intensity of the labeled cRNA after hybridization of the samples to the 
microarray probes (85).  The fluorescence measurement is facilitated by the use of a 
laser to excite the Cy3-labeled samples (85). The fluorescence from the labeled 
samples are detected and recorded in high-resolution TIFF images prepared for 
feature extraction analysis (85).  
The data generated from the gene expression experiments is extracted using Agilent 
Feature Extraction Software (82).  The software allows measurement of gene 
expression by extracting the information from probe features from microarray scan 
data (82). By the use of the Spike-In controls Agilent One Color microarray 
experiments can be analyzed with the Feature Extraction software which generates a 
Quality Control (QC) Report used for quality assessment of the microarray 
experiment (83). Agilent Feature Extraction Software automatically finds and places 
microarray grids, rejects outlier pixels, determines feature intensities and ratios, flags 
outlier pixels and calculates statistical confidences (86).The QC report contain 
statistical results and can be used to evaluate microarray performance such as the 
reproducibility and reliability of single microarray data (87). A QC Metric Set can be 
assigned the Feature Extraction (FE) Project (82), and the results appear as an 
evaluation table in the QC report (87). Most of the metrics included in the metric set 
evaluates the different laboratory steps such as the labeling, hybridization, washing 
and scanning (87). Thresholds are included in the metric sets and indicates if the data 
is in the expected range (“Good”) or out of the expected range (“Evaluate”) (87). The 
metrics can therefore determine if any problems during the experiment have arisen.   
4.2.4.1 Procedure  
Steps:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         
1. The scanner and the scanner PC was turned on and the Agilent Scan Control 
Software was opened before Start Slot and End Slot in addition to Profile 
AgilentHD_GX_1Color was selected 
2. The microarray slides were inserted into slide holders and the  assembled slide 
holders were placed in the scanner carousel, before it was verified that the 
38 
 
Scanner status in the main window said Scanner Ready and the scan was 
started 
3. When the scanning of the microarray slides was completed, Agilent Feature 
Extraction Software was opened at the scanner PC 
4. TIFF image was extracted by adding the image to be extracted to the FE 
Project, before setting the correct FE Project Properties and selecting the 
correct Extraction Set Configurations (the correct grid template and the correct 
protocol) before the extraction was started 
5. After the extraction was completed the QC reports for each extraction set was 
viewed and evaluated  
 
4.3 RNA Quality Assessment 
The Agilent 6000 Nano Assay evaluates RNA quality by the use of Agilent 2100 
Bioanalyzer (88). This quality characterization is important because experiments 
involving RNA such as genome-wide microarrays require high quality RNA. The 
assay contains RNA chips with an interconnected set of microchannels that is used for 
the separation of RNA fragments based on their size as they are driven through the 
channels by electrophoresis (89).  
After the analysis is performed the Agilent 2100 Expert Software provides a RNA 
Integrity Number (RIN) for each sample (88). The RIN number is a quantitative value 
for RNA integrity and is ranging from 1 to 10, representing the lowest and highest 
RNA quality, respectively. In addition to the RIN number, an electropherogram of 
each sample well window is generated (88). If the total RNA run is successful two 
distinct peaks representing the 18S and 28S ribosomal RNA in addition to one marker 
peak will be displayed in the elecropherogram (Figure 15) (88).  
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Figure 15. An electropherogram of the sample well window can be displayed after a total RNA sample 
run on the Agilent 2100 Bioanalyzer. One marker peak and two ribosomal peaks (18S and 28S) are the 
major features of a successful run (88). 
4.3.3 Procedure 
Steps: 
1. The RNA 6000 Nano gel matrix was equilibrated to room temperature for 30 
minutes before 550 µl of the matrix was dispensed to a filter spin and 
centrifuged at 1500 g +/- 20% for 10 minutes 
2. 65 µl filtered gel was dispensed into 0.5 ml RNase-free microfuge tubes. The 
tubes were stored at 4ºC and must be used within one month of preparation 
 
Preparation of the ladder: 
Steps:  
1. The ladder was dispensed to a 1.5 ml RNase-free microfuge tube before it was 
denatured at 70ºC for 2 minutes and placed directly on ice 
2. Aliquots were then prepared in 0.5 ml RNase-free microfuge tubes before 
stored at -70ºC 
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Preparation of the gel-dye mix: 
Steps:  
1. The RNA 6000 Nano dye concentrate was equilibrated to room temperature 
for 30 minutes before vortexed for 10 seconds and spinned down 
2. 1 µl of dye was added into a 65 µl aliquot of filtered gel and the solution was 
vortexed before the tube was centrifuged at 13000 g for 10 minutes, the 
prepared gel-dye mix had to be used within one day  
 
Loading the gel-dye mix: 
Steps:  
1. A new RNA 6000 Nano chip was placed on the chip priming station before 
9.0 µl of gel-dye mix equilibrated to room temperature for 30 minutes was 
dispensed to the well marked with a black G 
2. The plugger was positioned at 1 ml before the chip priming station was closed 
and the plugger was pressed until it was held by the chip 
3. The clip was released after 30 seconds, and after additional 5 seconds the 
plugger was pulled back  to 1 ml position 
4. The chip priming station was opened and 0.9 µl of gel-dye mix was dispensed 
in the two wells marked G 
 
Loading the Agilent RNA 6000 Nano Marker: 
Step:  
1. 5 µl of RNA 6000 Nano marker equilibrated to room temperature for 30 
minutes was dispensed in all 12 sample wells including the well marked with a 
ladder 
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Loading the ladder and samples: 
Steps:  
1. 1 µl of  prepared ladder kept on ice was dispensed in the well marked with a 
ladder before 1 µl of sample was dispensed in each of the 12 sample wells 
after the samples had been denatured at 70ºC for 2 minutes  
2. The chip was placed horizontally in the adapter of the IKA vortexer and 
vortexed for 1 minute at 2400 rpm  
3. 350 µl RNase Zap was dispensed into an electrode cleaner and placed in the 
Agilent 2100 bioanalyzer for 1 minute before 350 µl RNase-free water was 
dispensed into another electrode cleaner and placed in the bioanalyzer for 10 
seconds, then the lid was opened and the electrodes was dried for 10 seconds 
 
Starting the Agilent 2100 Bioanalyzer: 
Steps:  
1. The bioanalyzer was turned on, the chip was placed in the bioanalyzer within 
5 minutes after ladder and sample loading and Agilent 2100 expert software 
(Revision B.02.02 and higher) was opened before Eukaryotic Total RNA 
Nano Series II was selected at the bioanalyzer PC and the number of samples 
entered  
2. After the analysis was completed the chip was removed before the electrode 
cleaner containing  RNase-free water was placed in the bioanalyzer for 10 
seconds 
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4.4 RNA Quantification with Absorbance 
NanoDrop ND-1000 UV-VIS Spectrophotometer is used to measure among other the 
concentration of DNA and RNA and also to assess their purity (90). The 
spectrophotometer measures the absorbance of compounds absorbing at 230, 260 and 
280 nm.  
Quality assessment of template RNA and Cy-3 labeled cRNA is important for the 
outcome of gene expression experiments (82). The RNA should be of high quality and 
thus free of contaminants such as proteins, carbohydrates and organic solvents (82). In 
addition, the RNA should be intact and minimally degraded (82). Two ratios are used 
to assess high-quality RNA and include the A260/280 and A260/A230 ratios (82). The 
A260/280  ratio indicates the presence of contaminating proteins and should be 1.8 to 2, 
indicating no protein contaminants (82). In contrast, the A260/A230 ratio indicates the 
presence of organic compounds and cellular contaminants and should be above 2 (82).  
4.4.1 Procedure 
Steps: 
1. The sampling arm was opened and 1.5 µl RNase-free water was applied onto 
the lower measurement pedestal to clean it before the arm was closed. The 
Nanodrop software was started and Nucleic Acid Measurement (for RNA 
and DNA) or Microarray Measurement (for cRNA) was selected 
2. 1.5 µl distilled water was applied to initialize the instrument, and the sample 
type RNA-40 was selected before 1.5 µl distilled water was used to blank the 
instrument 
3. Then 1.5 µl of each sample was applied onto the lower measurement pedestal, 
and concentrations was measured (ng/µl) in addition to the A260/280 and 
A260/A230 ratios 
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4.5 Statistical Methods and Bioinformatics 
The statistical methods and bioinformatic tools used in this thesis are described in 
brief below. 
4.5.1 GeneSpring GX 
The GeneSpring GX Software (Version 11.5.1 – Build 138755) from Agilent 
Technologies is used among other to pre-process and analyze mRNA expression 
microarray data (91). The Feature Extraction files are uploaded to GeneSpring GX 
and the gene expression microarray data is automatically log2 transformed to remove 
negative numbers and 0 (91). The log2 transformation also serves as a basic 
normalization of the data. Several more advanced normalization methods are 
available to normalize the microarray data such as quantile and percentile 
normalization. Normalization of the fluorescent intensities of the microarray data is 
performed to minimize systemic non-biological variance such as RNA quantity 
differences, hybridization variability between microarrays and differences between 
manufactured microarrays. The in between sample normalization is performed to 
make microarray measurements comparable and to reveal differences due to 
biological variation and not due to technical variation. 50% percentile normalization 
calculates the 50
th
 percentile for each array and aligns the arrays by their 50
th  
percentile which corresponds to the median value (91). This method assumes that the 
50
th
 percentile intensity is similar for all samples. In contrast, quantile normalization 
assumes that the overall expression and the distribution of gene abundance is the same 
across arrays. When performing quantile normalization the data is therefore 
normalized so that the distribution of probe intensities is the same for all samples 
(91).  
Quality control on samples can be performed in GeneSpring GX to detect outlier 
samples (91). Quality control on samples is assessed by Principle Component 
Analysis (PCA) which is a covariance analysis. Principle components are vectors that 
reduce the microarray data into three dimensions. The PCA components 1, 2 and 3 
capture the most variance in the microarray data and are numbered according to their 
decreased significance (91). Detection of the major trends in the data set can be 
viewed in a 3D-scatter plot. The X, Y and Z axis correspond to principle component 
1, 2 and 3, respectively (91). When performing PCA on samples, each sample is 
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plotted according to its values for the first three Principal Components. The samples 
having similar scores for one or more components can be considered to have similar 
gene expression profile. To evaluate the similarity of samples within different 
condition groups the samples can be colored by experimental parameters. This may 
also identify influent parameters involved in the experiment.  
Quality control on probes is performed in GeneSpring GX by filtering the probe sets 
to remove low reliability probes (91). The probe sets can be filtered by expression, 
where a lower- and upper cutoff can be chosen. In addition, the probe sets can be 
filtered based on their flag values. The stringency of this filtering is adjusted by 
selecting specific types of flag calls and the number of samples in which the flag 
setting must pass (91). The default flag settings in GeneSpring GX flags the probes 
that are non-uniform, saturated and population outlayers as ‘compromised’ probes, 
while non-positive, non-significant and below background probes are flagged as ‘not 
detected’.   
4.5.2 Unsupervised hierarchical clustering in R 
Hierarchical clustering is a method that groups both samples and genes according to 
the similarity in their gene expression profiles. This can be performed unsupervised 
which organizes the samples without any predefined parameters to identify patterns 
and biological mechanisms within a data set. The results of the clustering are viewed 
in a dendrogram. In the dendrogram the samples that have a higher similarity in their 
expression profiles cluster more adjacent to each other than samples that show more 
differences in their expression profiles. In addition, the length of the branches in the 
dendrogram increases as the similarity decreases. Numerous similarity metrics can be 
used to capture related expression values between samples by calculating the distance 
or the correlation, such as euclidean distance or Pearson correlation (91). The 
calculation of the closeness is based either on trends or magnitude. Different linkage 
methods are also available to link all the samples in the cluster together, e.g. single, 
average, complete and centroide. By performing average linkage the average distance 
between all pairs are calculated and used to cluster the samples. Hierarchical 
clustering can be performed among other in the open statistical system R 
(http://windowxupdate.microsoft.com). Unsupervised clustering requires normalized 
gene expression values for all probes for the samples you want to include in the 
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cluster as input data. The R code for hierarchical clustering using pearson distance 
metric and average linkage is listed below: 
data<-read.table("allprobes_normalized.txt", 
header=T,sep="\t",na.strings="NA",row.names=NULL) 
 
data2<-data[,3:dim(data)[2]]  
 
m<-data.matrix(data2) ; rownames(m) <- data[,1];dim(m) 
 
c<-cor(m, method="pearson") 
d<-as.dist(1-c) 
hr <- hclust(d, method = "average", members=NULL) 
plot(as.dendrogram(hr), edgePar=list(col=1, lwd=2), horiz=F)  
4.5.3 4.5.8  Intrinsic subclassification  
Breast tumors can be classified into distinct subclasses by a method called intrinsic 
subclassification. This method was developed when the five subgroups were 
identified based on gene expression patterns by Sørlie and colleagues (92). The genes 
used for the classification were selected based on their similar expression level 
between tumors collected before and after neoadjuvant doxorubicin therapy from the 
same patient. A ‘intrinsic’ gene list of approximately 500 genes was created that 
consisted of genes which were most similar expressed between tumor samples from 
the same patient and which in addition showed the most variation in expression 
among tumors from different patients. For each of the five subclasses identified, a 
centroid consisting of the average expression for all of the ‘intrinsic’ genes was 
created. When performing intrinsic subclassification on tumor samples today, the 
Pearson correlation between the expression level of the ‘intrinsic’ genes in each tumor 
sample and the five centroids are calculated. Samples are then assigned to the subtype 
of the centroid with the largest correlation coefficient.   
4.5.4 Significance Analysis of Microarrays (SAM) 
Significance Analysis of Microarrays (SAM) is a software which is used to identify 
significant genes in a microarray data set (93). This multiple t-test was proposed and 
written by coworkers at Stanford University CA. SAM requires Windows, Microsoft 
Excel and the latest version of R. SAM can be used to perform numerous statistical 
analyses, such as quantitative, two class (unpaired and paired), one class, multiclass, 
survival analysis and many more. A two class SAM analysis (either unpaired or 
paired) requires normalized gene expression values in addition to a variable that 
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divides the samples into two groups as input data. The data must be in an Excel 
spreadsheet in which the first row contains information about the chosen variable and 
the remaining row consists of gene expression data.  
SAM measures the strength of the relationship between the gene expression values 
and the variable. Repeated permutations of the data are used to determine if any genes 
are differentially expressed between the two sample groups. Generally in the scientific 
literature the cut-off for significance is set to 5%. A p-value <0.05 indicates that the 
differences cannot be explained by chance. However, microarray analysis often 
involves many independent statistical tests performed on the same data set. False 
positive results are therefore expected. A parameter called delta in the SAM output 
window can be tuned to choose the cutoff for significance based on the false 
discovery rate (FDR), which corresponds to the rate of false positive results expected 
among the significant findings. The SAM output consists of a table with all the genes 
that are significant differentially expressed between the two groups chosen on the 
basis of the variable. Both positive and negative genes are viewed that correspond to 
the genes which are up- and down regulated, respectively. In addition, a fold change 
parameter that reflects how much the expression of each gene is different between the 
two groups are displayed. The gene list containing the significant genes can be used in 
further bioinformatic analyses. However, the gene lists often contains probes without 
annotations. Databases such as SOURCE (http://smd.stanford.edu/cgi-
bin/source/sourceBatchSearch) contain genetic and molecular annotations and can be 
used for this purpose.   
4.5.5 Hierarchical clustering in J-Express 
J-Express (http://jexpress.bioinfo.no/site/) is a bioinformatic and statistical software 
used for analyses of microarray data. The software is developed by a bioinformatics 
group at the Department of Informatics, University of Bergen, Norway and is owned 
by Molmine AS. Several statistical analyses can be performed in J-Express among 
other hierarchical clustering. When performing hierarchical clustering in J-Express 
microarray data containing columns with gene identifiers, rows with sample 
identifiers and expression values are uploaded to the software. Next, the similarity 
metric and the linkage method are selected, before the hierarchical clustering is 
performed.        
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4.5.6 Ingenuity Pathway Analysis (IPA) 
Ingenuity Pathway Analysis (IPA) (http://www.ingenuity.com) is a licensed software 
which enables pathway and gene analysis of biological data such as microarray data. 
The information in IPA is based on scientific literature and databases which is 
manually reviewed.  Gene lists from e.g. SAM can be used as input. IPA provides 
information about among other networks, molecular and cellular functions, chemical 
and molecular interactions and disease and disorder processes for a given gene set. 
Many of the results in IPA are provided with a p-value, a Benjamini-Hochberg p-
value which is corrected for multiple testing and a ratio which reflects the number of 
molecules from the input gene set that map to a specific pathway or list divided by the 
total numbers of molecules that are mapped by IPA to the same pathway or list.  
4.5.7 Gene Set Enrichment Analysis (GSEA) 
In Gene Set Enrichment Analysis (GSEA) prior-defined gene sets (e.g. from Gene 
Ontology or KEGG) are used to identify gene sets which are differentially expressed 
within two sample groups. GSEA can be performed in several software’s, such as 
GeneSpring GX and J-Express. In GSEA sets of genes rather than individual genes 
are analyzed for differentially expression between two experimental groups. By using 
statistics that evaluate each gene by itself it can be difficult to identify differences in 
expression if the gene only shows a moderate change. Therefore, GSEA is utilized to 
evaluate if many genes belonging to the same gene set are changed.  
4.5.8 SPSS 
IMB SPSS Statistics is a software which can be utilized to perform a number of 
statistical tests. Cross tabulation can be performed to measure the association between 
two-way tables. The statistics used for measuring the relationship is among other Chi-
square and Fisher’s exact test. Chi-square is not recommended if more than 1/5 of the 
cells have less than five expected observations. In those cases the Fisher’s exact test is 
preferred. One-Way ANOVA can also be performed in SPSS and is a parametric test 
which can be used for normal distributed data to compare if there is a significant 
difference in for instance mean expression level of a transcript between two groups. It 
is an extension of the two-sample t-test, and analysis of variance is used to test the 
hypothesis that several means are qual.  
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5. Results 
In this study the changes in mRNA expression in relation to doxorubicin therapy 
(before versus after doxorubicin exposure) were investigated as well as the 
association between mRNA expression profile and response to doxorubicin treatment. 
In addition, the gene expression profiles of samples with wild type and mutated TP53 
were studied. Analyses were performed to increase the understanding of the molecular 
mechanisms underlying doxorubicin effect on tumors and in addition to elucidate the 
mechanisms behind patients’ response to doxorubicin treatment.  
5.1 mRNA Expression Analysis 
The statistical analyses can be divided into four main parts: 1) mRNA expression in 
tumor tissue before versus after doxorubicin therapy, 2) mRNA expression and 
response to treatment, 3) mRNA expression and TP53 mutation status and 4) 
molecular subclassification based on gene expression profiles. Before statistical 
analyses can be performed the microarray data have to be normalized and filtered. 
The pre-processing and quality control of the samples and probes are described 
below.  
5.1.1 Pre-processing and quality control of microarray data 
Whole-genome mRNA analysis was performed according to standard procedure (see 
method chapter 4.2) using the Human GE 4x44K Microarray. 2 out of 131 samples 
failed the technical lab quality control, leaving 129 samples for further analyses. Pre-
processing of the microarray data was performed in GeneSpring GX Version 11.5.1. 
The microarray data were 1) log2 transformed and normalized using 50% percentile 
normalization, 2) filtered by expression (lower cut off 10%, upper cut off 100%) 
giving 26635 remaining probes and 3) filtered by flags (detected and not detected) 
resulting in 26270 remaining probes. The control- and spike-in probes (n=36) were 
deleted yielding a total of 26234 probes, that corresponded to 14046 unique genes, 
available for data analyses.  
Principle Component Analysis (PCA) was performed to assess sample uniformity and 
quality. 3D-scatter plots were created on 1) normalized and unfiltered data, 2) on data 
filtered by expression and 3) on data filtered both by expression and by flags. By 
performing quality control on the original 129 experimental samples one sample (BC 
49 
 
40-BE) was found to be an outlier in the PCA analysis. In addition, this sample had a 
different distribution of signal intensities in the QC report from Feature Extraction 
compared to the other samples (Figure 16). When performing hierarchical clustering 
BC 40-BE clustered separately and based on the combination of these findings the 
sample was removed, leaving a total of 128 samples (56 before and after pairs and 16 
‘single’ samples consisting of eight before and eight after samples) available for 
statistical-and bioinformatic analyses. 
 
Figure 16. Probe signal distribution. The signal intensities for BC 40-BE (a) compared to another, 
representative sample in the experiment (b). The histogram for BC 40-BE is not as well distributed as 
for the other sample and show overall lower signal intensity. This sample was excluded from any 
further statistical analyses.  
After the BC 40-BE sample was removed, new PCA plots were generated of the 
remaining 128 samples. One sample outlier was observed in the PCA plot created on 
only normalized array data (Figure 17). However, when a new plot was generated 
using normalized and filtered data this sample clustered together with the rest of the 
samples. No technical aberrations were observed for this sample and it was therefore 
not excluded from further statistical analyses.  
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Figure 17. Principle Component Analysis (PCA). Quality control on samples was performed by PCA 
and the creation of 3D-scatter plots where samples are displayed in respect to the first three principle 
components.  One sample outlier of the total 128 experimental samples is indicated with a red circle in 
the PCA plot created on normalized, unfiltered data (a). The PCA plots created on data filtered only by 
expression (data not shown) and on data filtered both by expression and by flags (b) are almost 
identical. The outlier sample (indicated again with a red circle) has now merged with the rest of the 
samples. This sample was therefore not omitted from further analyses.  
 
5.2 mRNA Expression Profile Before and After Doxorubicin 
Therapy 
A major part of this study was the investigation of the mRNA expression levels in 
breast cancer tumor tissue collected before and after doxorubicin therapy. For the 
samples collected before and after treatment (termed BE and AF) the analysis of the 
alterations in gene expression pattern may highlight the pathways induced and/or 
repressed by doxorubicin exposure. 
5.2.1 PCA of before and after samples 
A 3D PCA scatter-plot was generated of the 128 experimental samples by using the 
normalised and filtered probe list containing 26234 probes to evaluate the mRNA 
expression similarity between samples collected before (n=64) and after (n=64) 
doxorubicin treatment (Figure 18). The scatter plot revealed that samples collected 
before and after doxorubicin treatment were grouped in different areas in the plot. The 
before samples were mostly shifted in one area, while the after samples were mostly 
shifted in another indicating an overall difference between the two groups.  
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Figure 18. 3D-scatter plot of before and after samples. Before samples (n=64) are indicated in blue, 
while after samples (n=64) are shown in red.  The PCA graph illustrates that samples within the same 
experimental condition i.e. treatment status mainly group together.  
 
5.2.2 Unsupervised hierarchical clustering  
Unsupervised hierarchical clustering by mRNA expression of the 128 tumor samples 
was performed in R version 2.14.1 (Figure 19). The normalized and filtered 
microarray data containing 26234 probes were used as input. Pearson correlation and 
average linkage were chosen as the distance metric and the linkage method, 
respectively. In the hierarchical cluster dendrogram the tumor samples were organized 
according to the similarities in their gene expression profile without any predefined 
parameters. The cluster analysis did not separate the before and after samples into two 
clear clusters. However, the subcluster that contained the majority of the samples 
could be divided into three main clusters (see Figure 19). Cluster 1 contained 33 after 
samples and 8 before samples, cluster 2 contained 31 before samples and 15 after 
samples while cluster 3 contained 8 after samples and 6 before samples. A significant 
different distribution of before and after samples between the three main clusters 
indicated in Figure 19 was observed using Pearson Chi-Square test (p-value=2.44E-
5). The two ends on each side of the three main clusters contained both a majority of 
after samples.  
The cluster analysis separated the majority of the before and after pairs collected from 
the same patient. Of the 56 pairs in the sample set, 18 of the pairs clustered together 
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while the rest of the pairs were separated. Nine of the 18 pairs that clustered together 
were collected from patients characterized as having a stable disease and/or minimal 
change (SD/MC) to doxorubicin therapy, and nine pairs were collected from patients 
assessed with a partial response (PR) to therapy. The majority of the pairs found to 
cluster together clustered in the ‘before’ cluster/cluster 2 in Figure 19.  
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Figure 19. Unsupervised hierarchical clustering by gene expression. (A) The 128 samples were 
organized according to similarity in their gene expression patterns using Pearson distance metric, 
average linkage and 26234 probes. Samples collected before and after doxorubicin therapy are assigned 
BE and AF at the end of each sample name and colored blue and red, respectively. An asterisk (*) 
beneath the dendrogram indicates samples collected before and after doxorubicin therapy from the 
same patient clustering together. (B) Patient response to doxorubicin and primary tumor characteristics 
are indicated: response: partial response (purple), stable disease and/or minimal change (green); 
estrogen receptor status: ER negative (white), ER positive (black); histological grade: grade 1 (white), 
grade 2 (grey), grade 3 (black); TP53 mutation status: wild type (white), mutated (black).   
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5.2.3 SAM analysis of tumor samples before and after therapy 
SAM analysis was performed on the normalized and filtered mRNA expression data 
to detect genes differentially expressed between samples collected before and after 
doxorubicin treatment. The analysis was performed both on the total number of 
experimental samples (n=128, 64 before and 64 after) and on the subset of sample 
pairs collected before and after doxorubicin therapy from the same patient (n=112 
representing 56 pairs). SAM analysis on the expression data from all samples 
increases theoretically the power to detect differences because more samples are 
included in the analysis, while the removal of the 16 ‘single’ samples may give a 
“cleaner” result of the differences between the samples collected before and after 
doxorubicin therapy, through the embedded correction for intratumor differences.  
SAM analysis performed on microarray data from all the 128 experimental samples 
detected 6387 probes to be significantly differentially expressed between the before 
and after samples (FDR≈0%) (Figure 20). In all, 2889 probes were found to be up 
regulated while 3498 probes were found to be down regulated in the after samples.  
 
Figure 20. SAM analysis, all samples. Two class unpaired analysis revealed 6387 probes to be 
differentially expressed between before and after samples (FDR≈0%). The red (n=2889) and the green 
(n=3498) probes are up- and down regulated respectively in the after samples.  
55 
 
SAM analysis performed on mRNA expression data from the 56 before and after pairs 
revealed 6482 probes to be significant differentially expressed between the two 
groups (FDR≈0)  (Figure 21). A total of 3040 up regulated and 3442 down regulated 
probes were revealed in the after samples. 
 
Figure 21. SAM analysis, paired samples. SAM analysis performed on the before and after pairs (n=56 
pairs, 112 samples). Two class paired analysis explored 6482 probes to be significant differentially 
expressed between the before and after samples (FDR≈0%). The red (n=3040) and the green (n=3442) 
probes are up- and down regulated in the after samples respectively.  
Comparing the fold change of the genes from both the unpaired and paired SAM 
analysis revealed a much higher fold change for the genes up regulated after therapy 
than for the genes down regulated after therapy. The genes showing the largest fold 
change in either direction, i.e. top 25%, from both the unpaired and the paired SAM 
analysis were further analyzed using Ingenuity Pathway Analysis (IPA). Selected 
genes that were shown to be significant differentially expressed by SAM analysis, and 
that were found in the list containing genes having the 25% fold change, were further 
investigated using IMB SPSS Statistics 18. This analysis was performed to confirm to 
which extent the genes were differentially expressed between the before and after 
samples by using One-Way ANOVA. Two of the up regulated (FOS, CYR61) and two 
of the down regulated (FBXO11, NIT2) genes from the unpaired analysis were 
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visualized by ANOVA plot (Figure 22). The mean mRNA expression level for the 
four genes in the before and after samples is illustrated in Figure 22. By using One-
Way ANOVA all the genes were found to have a significant difference in means 
(p<0.05) between the two groups. 
Figure 22. The distribution of mRNA expression level of selected genes in before and after samples. 
FOS and CYR61 were found to be up regulated in the after samples, while FBXO11 and NIT2 were 
found to be down regulated in the after samples by SAM analysis. By performing One-Way ANOVA 
the four genes were shown to have a significant difference in means between the two groups (p-
value<0.05). The distribution of expression levels between the before (BE) and the after (AF) samples 
is visualized in the box plot. The box plot shows the 75
th
 (upper edge of box), 50
th
 (line in the box) and 
25
th
 (bottom edge) percentile while the whiskers gives the 1.5 interquartile range. Outliers are shown 
with small black circles.  
The probes found to be differentially expressed between samples collected before and 
after treatment from the unpaired SAM analysis (n=6387) were used to cluster the 128 
samples (Figure 23). In this cluster analysis, only four pairs were found to cluster 
together indicating a greater separation of the before and after samples collected from 
the same patient compared to using all probes in the microarray data (see chapter 
5.2.2).  
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Figure 23. Hierarchical clustering using only the probes found to be differentially expressed between 
before and after samples from SAM. Samples collected before doxorubicin treatment are shown in blue 
and samples collected after treatment are shown in red. An asterisk (*) beneath the dendrogram 
indicates before and after pairs from the same patient that clustered together.   
 
5.2.4 Ingenuity Pathway Analysis of genes differentially expressed between 
before and after samples 
The probe lists containing the genes differentially expressed between before and after 
samples from both the unpaired and the paired SAM analysis were extracted and 
further analyzed using Ingenuity Pathway Analysis (IPA). Before the analyses were 
performed, the probe lists from SAM were pre-processed. First, the gene names of the 
un-annotated probes were updated where possible using SOURCE, before the 
remaining un-annotated probes were deleted. Probes with the top 25% fold change 
were extracted and the redundant genes removed before uploading the list of genes to 
IPA. A small subset of genes was not recognized in IPA and these genes were 
therefore excluded in the analyses. The number of probes and unique genes up- and 
down regulated, after doxorubicin therapy, in both the unpaired and paired analysis 
are shown in table 3.    
Table 3. Overview of probes from the SAM analyses and genes included in IPA analyses. The probes 
up- and down regulated after doxorubicin treatment from the unpaired and paired SAM analysis are 
shown. Before IPA analyses were performed, the un-annotated probes were deleted and probes with the 
top 25% fold change extracted.  The unique genes these probes represented were uploaded to IPA. The 
last row in the table specifies the total number of genes included in the IPA analysis.  
 Unpaired  Paired  
 Up regulated  Down regulated  Up regulated  Down regulated  
Probes from SAM  2889  3498  3040  3442  
Probes after 
deletions  
2633  2414  2770  2392  
Probes with top 
25% fold change  
658  603  692  598  
Unique genes  573  559  603 557 
Genes included in 
IPA analysis   
567  548  594 536 
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A total of 534 genes were found to be identical between the up regulated genes, 
having the top 25% fold change, from the unpaired and paired comparison of before 
and after samples. For the unpaired list, 39 genes were unique compared to 69 unique 
genes for the paired gene list. Likewise, 369 genes were found to be equal between 
the genes down regulated, with the top 25% fold change, after doxorubicin treatment 
from the unpaired and paired SAM analysis. In addition, 190 genes were found 
exclusively in the unpaired list while the paired list contained additional 188 unique 
genes. Venn diagrams illustrating the gene similarity between the up- and down 
regulated genes from the unpaired and paired analysis are shown in Figure 24.  
 
Figure 24. Venn diagrams of genes, having the top 25% fold change, from the unpaired and paired 
comparison of before and after samples. The Venn diagram illustrates that 534 genes are equal between 
the unpaired and paired analysis of genes up regulated after doxorubicin therapy (a). A total of 369 
down regulated genes were found to be equal between the two gene lists containing genes down 
regulated after treatment (b).  
For both the up- and down regulated gene lists, the genes showing the largest fold 
change, i.e. top 25%, were uploaded to IPA. IPA of genes up regulated after treatment 
with doxorubicin are described first, followed by IPA of the genes down regulated 
after therapy.  
5.2.4.1 IPA on genes up regulated after doxorubicin treatment  
The genes up regulated, showing the top 25% fold change, after doxorubicin therapy 
provided from the unpaired (n=567) and paired (n=594) before and after sample 
comparison were uploaded to IPA to identify functions and pathways enriched within 
the lists. Tables containing the molecular and cellular functions, canonical networks, 
transcription factors and tox lists overrepresented within the gene lists are listed below 
(Table 4-7). 
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The IPA analysis revealed many molecular and cellular functions overrepresented in 
the list of genes with top 25% fold change up regulated after treatment for both the 
unpaired and paired gene list. To identify the most significant functions a Benjamini-
Hochberg threshold value was selected. A threshold value of 0.05 revealed 65 
enriched functions in both the unpaired and paired gene lists. To reduce this number, a 
threshold value of 1.0E-13 was selected for both analyses, and revealed a total of six 
and eight functions significantly overrepresented in the list of genes up regulated from 
the unpaired and paired analysis, respectively. The IPA analyses indicated that the 
molecular and cellular functions overrepresented in the list of genes up regulated after 
treatment were almost identical between the gene lists provided from comparison of 
all and paired before and after samples (Table 4).  
Table 4. The most significant molecular and cellular functions enriched in the list of unique genes, 
with top 25% fold change, up regulated after doxorubicin treatment. The functions displayed are 
provided from the comparison of unpaired (a) and paired (b) before and after samples. The Benjamini-
Hochberg multiple testing correction p-value (B-H p-value) and the number of molecules in the 
uploaded data set associated with each specific function are displayed. 
a) Molecular and Cellular Functions overrepresented in the list of unique genes up 
regulated after therapy, unpaired analysis (n=567)  
Name B-H P-value  # molecules  
Cancer  9.10E-31 – 3.40E-03 266 
Reproductive System Disease  9.10E-31 – 6.85E-04 183 
Cardiovascular System Development and 
Function  
4.53E-24 – 3.43E-03 155 
Organismal Development  4.52E-24 – 3.08E-03 182 
Cellular Movement  5.42E-21 – 3.40E-03 160 
Cell Morphology 2.49E-14 – 3.40E-03 180 
b) Molecular and Cellular Functions overrepresented in the list of unique genes up 
regulated after therapy, paired analysis (n=594) 
Name  B-H P-value # molecules 
Cancer 2.90E-33 – 3.09E-03 282 
Reproductive System Disease 2.90E-33 – 9.74E-04 192 
Cardiovascular System Development and 
Function 
3.23E-25 – 2.86E-03 164 
Organismal Development 3.23E-25 – 2.92E-03 204 
Cellular Movement 6.98E-23 – 2.86E-03 183 
Cellular Growth and Proliferation 3.55E-15 – 2.71E-03 229 
Tissue Development 4.52E-15 – 2.92E-03 242 
Cell Morphology 3.65E-14 – 1.90E-03 193 
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The top canonical pathways overrepresented in the list of genes having the top 25% 
fold change up regulated after therapy, extracted from the SAM analysis of both 
unpaired and paired samples are shown in Table 5. A Benjamini-Hochberg threshold 
value was selected to detect the most significantly enriched pathways within the gene 
lists. A total of ten pathways were discovered to be overrepresented in the list of up 
regulated genes from the unpaired list when a threshold value was set to 0.05. 
Additionally, the same threshold value identified nine pathways enriched in the list of 
genes up regulated from the paired analysis. The analysis revealed that the enriched 
canonical pathways were strongly overlapping within both gene lists.  
Table 5. The most significant canonical pathways overrepresented in the list of genes up regulated 
after therapy, with the top 25% fold change. The pathways are extracted from the SAM analysis of both 
the unpaired (a) and the paired (b) before and after samples. For each canonical pathway the 
Benjamini-Hochberg multiple testing correction p-value and the ratio (genes included in the imported 
data set/ the total number of genes in the canonical pathway) are provided. 
a) Top Canonical Pathways overrepresented in the list of unique genes up regulated after 
therapy, unpaired analysis (n=567)  
Name  B-H P-value  Ratio  
Hepatic Fibrosis/Hepatic Stellate Cell 
Activation  
3.66E-05  20/142  
Role of Osteoblasts, Osteoclasts and 
Chondrocytes in Rheumatoid Arthritis  
2.39E-03  22/229  
Human Embryonic Stem Cell Pluripotency  5.58E-03  15/144  
Complement System  8.73E-03  7/34  
Role of Macrophages, Fibroblasts and 
Endothelial Cells in Rheumatoid Arthritis  
8.73E-03  24/324  
Atherosclerosis Signaling 1.33E-02 13/125 
Wnt/β-catenin Signaling 1.7E-02 16/171 
Leukocyte Extravasation Signaling  4.09E-02 16/192 
Glioblastoma Multiforme Signaling 4.09E-02 14/162 
PTEN Signaling 4.69E-02 11/121 
b) Top Canonical Pathways overrepresented in the list of unique genes up regulated after 
therapy, paired analysis (n=594)  
Name  B-H P-value  Ratio  
Hepatic Fibrosis/Hepatic Stellate Cell 
Activation 
4.25E-06 22/142 
Human Embryonic Stem Cell Pluripotency 2.59E-04 18/144 
Role of Osteoblasts, Osteoclasts and 
Chondrocytes in Rheumatoid Arthritis 
4.04E-03 22/229 
Role of Macrophages, Fibroblasts and 
Endothelial Cells in Rheumatoid Arthritis 
4.17E-03 26/324 
Caveolar-mediated Endocytosis Signaling 5.2E-03 11/83 
Leukocyte Extravasation Signaling 5.2E-03 19/192 
Atherosclerosis Signaling 5.66E-03 14/125 
Complement System 7.42E-03 7/34 
Wnt/β-catenin Signaling 8.7E-03 17/171 
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IPA also identifies transcription factors overrepresented as gene expression regulators 
within the list of genes analyzed. The top five transcription factors enriched as gene 
expression regulators of the list of up regulated genes, with the top 25% fold change, 
in the unpaired and paired analysis are listed in Table 6. The transcription factor that 
regulated the highest number of target molecules in both the unpaired and paired gene 
list was found to be p53.   
Table 6. The top five transcription factors overrepresented in the list of unique genes, with the top 25% 
fold change, up regulated after therapy discovered by the comparison of unpaired (a) and paired (b) 
before and after samples. The p-value and the number of target molecules for each transcription factor 
are shown. The p-values are not corrected for multiple testing.  
 
The most significant tox lists enriched in the list of up regulated genes, having the top 
25% fold change,  identified from the comparison of all before and after sample and 
from only the paired samples are shown in Table 7. A Benjamini-Hochberg threshold 
set to 0.05 identified nine significant enriched tox lists in the list of up regulated genes 
from the unpaired analysis. A total of eleven significant tox lists overrepresented in 
the list of genes from the paired analysis were revealed with the same threshold value. 
The tox lists enriched in the up regulated genes from both the unpaired and paired 
analysis contained tox functions involved in cardiotoxicity, hepatotoxicity and 
nephrotoxicity.  
 
 
a)               Unpaired  b)                 Paired  
Top Transcription Factors overrepresented 
in the list of genes up regulated after 
therapy (n=567)  
Top Transcription Factors overrepresented 
in the list of genes up regulated after therapy 
(n=594)  
Transcription 
Regulator  
P-value of 
overlap  
# targets  Transcription 
Regulator  
P-value of 
overlap  
# targets  
TP53  9.53E-11  83  KLF2 6.13E-13  29 
SP1  1.21E-10  49  SP1 1.03E-11  53 
KLF2  2.00E-10  25  SP3 1.24E-11  32 
SP3  3.09E-10  29  TP53 7.61E-11  87 
FOXL2  3.93E-09  15  SMAD3 2.32E-10  29 
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Table 7. The most significant tox lists overrepresented within the list of  genes up regulated, having the 
top 25% fold change, in the unpaired (a) and paired (b) before and after sample analysis. For each tox 
list the Benjamini-Hochberg multiple testing correction p-value and the ratio (genes included in the 
imported data set/ the total number of genes in the tox list) are provided.  
 
5.2.4.2 IPA on genes down regulated after doxorubicin treatment  
Genes down regulated after doxorubicin therapy, having the top 25% fold change, 
extracted from the SAM analysis of all before and after samples (n=548) and of paired 
before and after samples (n=536), were further investigated in IPA. The IPA analyses 
were performed to reveal information of the given gene sets, including molecular and 
cellular functions, top canonical pathways, top transcription factors and top tox lists 
overrepresented in the genes down regulated after treatment.  
A Benjamini-Hocherg threshold value was selected to detect the most significant 
molecular and cellular functions enriched in the list of genes, with the top 25% fold 
change, down regulated after therapy. When the Benjamini-Hochberg threshold value 
a) Top Tox Lists overrepresented in the list of genes up regulated after therapy, unpaired 
analysis (n=567) 
Name  B-H P-value  Ratio  
Acute Renal Failure Panel (Rat)  1.6E-08 16/62 
Cardiac Hypertrophy  1.05E-06 33/318 
Hepatic Fibrosis  8.36E-06 15/84 
Hepatic Stellate Cell Activation  5.48E-04 8/35 
Liver Proliferation  6.13E-04 18/170 
Persistent Renal Ischemia-Reperfusion 
Injury (Mouse) 
3.47E-03 6/30 
Increases Renal Proliferation 8.5E-03 8/56 
Cardiac Fibrosis 1.09E-02 12/124 
Cardiac Necrosis/Cell Death 3.56E-02 14/179 
b) Top Tox Lists overrepresented in the list of genes up regulated after therapy, paired 
analysis (n=594) 
Name  B-H P-value  Ratio  
Acute Renal Failure Panel (Rat) 2.93E-11 19/62 
Cardiac Hypertrophy 8.66E-09 38/318 
Hepatic Fibrosis 3E-06 16/84 
Persistent Renal Ischemia-Reperfusion 
Injury (Mouse) 
6.66E-04 7/30 
Hepatic Stellate Cell Activation 6.66E-04 8/35 
Increases Renal Proliferation 2.91E-03 9/56 
Liver Proliferation 2.91E-03 17/170 
Cardiac Fibrosis 5.63E-03 13/124 
Cardiac Necrosis/Cell Death 2.39E-02 15/179 
Renal Glomerulus Panel (Human) 2.54E-02 4/17 
Oxidative Stress 3.74E-02 7/57 
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was set to 0.05, only one molecular and cellular function was identified 
overrepresented in the list of genes down regulated after doxorubicin therapy from the 
unpaired analysis. Two molecular and cellular functions were identified enriched in 
the list of down regulated genes from the paired analysis with the same threshold. The 
functions are displayed in Table 8. 
Table 8. The most significant molecular and cellular functions overrepresented in the list of genes, 
with the top 25% fold change, down regulated after doxorubicin treatment provided from the 
comparison of unpaired (a) and paired (b) before and after samples. The Benjamini-Hochberg multiple 
testing correction p-value and the number of molecules in the data set associated with each specific 
function are displayed. 
 
Only one canonical pathway was revealed by IPA analysis to be enriched in the list of 
genes, with the top 25% fold change, down regulated after doxorubicin treatment 
obtained from the comparison of unpaired before and after samples. This pathway 
was “EIF2 Signaling” with a Benjamini-Hochberg multiple testing correction p-value 
(B-H p-value) of 7.3E-05 and a ratio of 19/193 (genes included in the imported data 
set/ the total number of genes in the canonical pathway). The same canonical pathway 
was found to be enriched in the list of genes down regulated after doxorubicin 
therapy, having the top 25% fold change, from the paired analysis. In the paired 
analysis “EIF2 Signaling” had a Benjamini-Hochberg p-vale of 1.84E-04 and a ratio 
of 18/193.  
The transcription factors overrepresented as gene expression regulators within the list 
of down regulated genes, with the top 25% fold change, from the unpaired and paired 
list are shown in Table 9. Some of the transcription factors were found to overlap 
between the unpaired and paired analysis. 
a) Molecular and Cellular Function overrepresented in the list of genes down regulated 
after therapy, unpaired analysis (n=548)  
Name B-H P-value  # molecules  
RNA Post-Transcriptional Modification 4.94E-03 – 381E-01 25 
b) Molecular and Cellular Functions overrepresented in the list of genes down regulated 
after therapy, paired analysis (n=536) 
Name B-H P-value  # molecules  
RNA Post-Transcriptional Modification 8.00-06 – 3.60E-01 29 
Cancer 3.51E-02 – 3.60E-01 46 
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Table 9. Top five transcription factors overrepresented in the list of genes, having the top 25% fold 
change, down regulated after doxorubicin treatment discovered by the comparison of unpaired (a) and 
paired (b) before and after samples. For each transcription factor the p-value and number of target 
molecules are displayed. The p-values are not corrected for multiple testing. 
 
No tox lists were identified as being significantly overrepresented within the list of 
genes down regulated after doxorubicin treatment obtained from the before and after 
comparison of either the unpaired or paired samples.  
 
5.3 mRNA Expression Profile and Response to Doxorubicin 
The patients, in which the tumor samples included in this thesis were collected from, 
were evaluated with three different responses to doxorubicin. The patients who 
obtained a stable disease and/or minimal change were categorized in the same group 
as non-responders (SD/MC). The patients which obtained a partial response were 
categorized as responders (PR).   
5.3.1 The association between clinical factors and response 
To investigate the relationship between treatment response and different clinical 
parameters such as ER status, grade and TP53 mutation status cross tabulation was 
performed in IMB SPSS Statistics 18. The analysis revealed a significant association 
between ER status of the samples collected after doxorubicin therapy and response 
(Fisher’s Exact 2-sided p-value=0.017). No significant association was found between 
grade or TP53 mutation status and response.   
 
 
a)               Unpaired  b)                 Paired  
Top Transcription Factors overrepresented 
in the list of genes up regulated after 
therapy (n=567)  
Top Transcription Factors overrepresented 
in the list of genes up regulated after therapy 
(n=594)  
Transcription 
Regulator  
P-value of 
overlap  
# targets  Transcription 
Regulator  
P-value of 
overlap  
# targets  
TP53  9.53E-11  83  KLF2 6.13E-13  29 
SP1  1.21E-10  49  SP1 1.03E-11  53 
KLF2  2.00E-10  25  SP3 1.24E-11  32 
SP3  3.09E-10  29  TP53 7.61E-11  87 
FOXL2  3.93E-09  15  SMAD3 2.32E-10  29 
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5.3.2 PCA of two different response groups 
PCA analysis was performed to investigate if it were possible to separate the two 
different response groups based on their overall gene expression profiles (Figure 25). 
The normalized and filtered probe list containing 26234 probes was used in the 
analysis. The PCA scatter plot illustrated that samples collected from doxorubicin 
responders (n=55) and non-responders (n=73) clustered together. This may indicate 
that the expression profiles of the samples in the two response groups are similar.  
Figure 25. 3D-scatter plot of the samples collected both before and after treatment from patients with 
different response to doxorubicin. Samples collected from patients assessed with stable disease and/or 
minimal change (SD/MC) (n=73) are shown in blue, while samples taken from patients assessed with 
partial response (PR) (n=55) are indicated in red. The PCA plot does not show an apparent separation 
of the two groups.     
5.3.3 SAM analysis of tumor samples from responders and non-responders 
To identify genes differentially expressed between doxorubicin responders and non-
responders SAM analysis was performed. The normalized and filtered mRNA 
expression data were used as input. SAM was performed on the before and after 
samples separately, in addition to the delta values for each of the before and after 
pairs (the differences in expression between the before and the after sample for a 
given patient, calculated by extracting the expression value of the after sample from 
the expression value of the before sample for each pair). The analyses of before and 
after samples were performed to evaluate if the expression profiles were predictive for 
response. The analysis of delta values was performed to assess if the two response 
groups had different capability to induce or repress the expression of genes. The 
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results from the three SAM analyses of responders and non-responders revealed that 
no genes were significantly differentially expressed between the patients who 
obtained a stable disease and/or minimal change and the patients who achieved a 
partial response to doxorubicin treatment. Another approach was then performed by 
using only the probes which were shown to be differentially expressed between the 
before and after samples revealed by SAM analysis (described in chapter 5.2.3). SAM 
analyses were performed on before samples, after samples and delta expression values 
utilizing the 6482 probes found to be differentially expressed between the paired 
before and after sample analysis. However, no significant genes were revealed to be 
differentially expressed between the two response groups.  
5.3.4 Gene Set Enrichment Analysis (GSEA) 
Since no individual genes were found to be differentially expressed by the comparison 
of doxorubicin responders and non-responders, Gene Set Enrichment Analysis 
(GSEA) was performed. This method analyses sets of genes rather than looking at 
each gene by itself. GSEA was performed in GeneSpring GX Version 12 by using the 
normalized and filtered microarray data. The GSEA did not reveal any significant 
gene sets to be differentially expressed between the doxorubicin responders and non-
responders.     
5.3.5 Statistical testing of p53 target genes 
 The IPA analysis of genes differentially expressed between samples collected before 
and after doxorubicin treatment revealed p53 as the transcription factor regulating the 
highest number of target genes with the top 25% fold change up regulated after 
treatment (see chapter 5.2.4.1). Given that p53 status has previously been associated 
to doxorubicin action and resistance, SAM analysis was performed using the p53 
target genes (n=87) from the paired before and after sample analysis to evaluate if 
these genes could be connected to doxorubicin response. Analyses of before (n=64) 
and after (n=64) samples in addition to delta expression values from the before and 
after pairs (n=56) uncovered several significantly differentially expressed genes in 
samples collected from patients assessed with partial response to doxorubicin 
compared to those with stable disease and/or minimal change. A total of six 
(FDR≈0%) and 30 (FDR=3-4%) significant up regulated genes were found in the 
samples collected from the responders using before and after samples, respectively. 
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By using delta values seven genes (FDR≈0%) were revealed to have a higher delta in 
the doxorubicin responders representing a bigger change in expression following 
treatment. The genes from the SAM analyses of before samples and delta values had a 
FDR≈0%, while the genes from the analysis of after samples had a higher FDR. 
Hence only the genes revealed to be up regulated in samples collected from patients 
assessed as doxorubicin responders from the SAM analysis of before samples, and the 
genes that were shown to have a higher delta in samples from patients with partial 
response by using delta values are shown in Table 10.  
Table 10. p53 target genes differentially expressed between samples collected from patients 
characterized as doxorubicin responders (PR) and non-responders (SD/MC). Six genes (FDR≈0%) 
were found to be significant up regulated in before samples from patients with a partial response 
compared to those with stable disease and/or minimal change (a). When applying the delta expression 
values seven genes (FDR≈0%) were revealed to have a higher delta in samples collected from patients 
assessed as doxorubicin responders (b). The average expression values and delta values in addition to 
the absolute difference in expression and delta values of the samples within the two response groups 
are shown. The list is sorted according to gene name. 
 
 
 
  
a) Before samples 
   Gene name Average expression, PR Average expression, 
SD/MC 
Absolute difference in 
expression 
CDC42EP3 1.59 1.23 0.36 
CTGF 2.75 2.11 0.64 
DKK3 4.73 4.3 0.43 
ITGB4 3.04 2.63 0.41 
JUNB 5.54 5.26 0.28 
PHILDA1 -0.79 -1.16 0.37 
b) Delta expression values 
   Gene name Average delta, PR Average delta, 
SD/MC 
Absolute difference in 
delta 
AKAP12 0.58 -0.52 1.1 
COL14A1 2.18 0.94 1.24 
DUSP1 2.57 1.74 0.83 
EGR1 3.3 2.53 0.77 
HIC1 1.46 0.85 0.61 
IGF1 2.32 1 1.32 
MMPP23B 2.18 0.94 1.24 
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A graphical illustration of the relationship between the p53 target molecules were 
generated in IPA and are shown in Figure 26. All direct relationships between the 
uploaded genes observed in humans and cancer specifically were selected in IPA. IPA 
analysis also revealed three canonical pathways enriched, “PTEN Signaling”, “IGF-1 
Signaling” and “HER-2 Signaling in Breast Cancer”, within the list of p53 target 
molecules when a Benjamini-Hocherg threshold value was set to 0.001.     
 
Figure 26. The relationship between p53 target molecules. The p53 target genes that were found to be 
up regulated in doxorubicin responders from the analysis of before samples are illustrated in blue, 
while the p53 target genes found to have a higher delta in doxorubicin responders are shown in pink. 
The location of the molecules in addition to the connection between them is illustrated in the figure. 
The canonical pathways (CP)  included are enriched signaling pathways within the uploaded genes.  
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5.4 mRNA Expression Profile and TP53 Mutation Status 
Certain TP53 mutations have been shown to predict for resistance to doxorubicin in 
breast cancer patients. Additionally, p53 has also been shown to modulate 
topoisomerase activity. The comparison between the mRNA expression profiles of 
samples containing wild type and mutated p53 are described below.  
5.4.1 PCA of samples with different TP53 mutation status 
PCA was performed on both before and after samples with wild type (n=99) and 
mutated (n=29) p53 to evaluate the differences in gene expression between the two 
groups (Figure 27), by using the normalized and filtered probe list containing 26234 
probes. The scatter plot indicated that samples with different TP53 mutation status do 
not separate completely. However, it appears that there is a certain distribution of the 
samples within the two groups. Samples with mutated p53 group mainly in one side 
of the PCA plot, while samples with wild type p53 group for the most part in another 
side of the plot. 
Figure 27. 3D scatter-plot of samples with different TP53 mutation status. Samples with wild type p53 
(n=99) are shown in red, while samples containing mutated p53 (n=29) are shown in blue. The PCA 
plot reveals that the samples do not separate perfectly. However, the graph may give the impression 
that samples with mutated p53 group mainly to the left, while samples with wild type p53 group mainly 
to the right. It is important to notice that the PCA plot includes both before and after samples. When 
focusing on the before and after samples separately the same trend was seen (data not shown).    
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5.4.2 SAM analysis of tumor samples with wild type and mutated p53 
To investigate if genes were differentially expressed between the samples having a 
wild type p53 compared to those that had mutated p53 SAM analysis was performed. 
Delta expression values were used in the analysis, which correspond to the differences 
in expression between the samples collected before and after doxorubicin therapy 
from the same patient. The 112 samples representing 56 pairs were therefore used in 
this analysis. The comparison of the samples which had wild type 53 to those that had 
mutated p53 revealed 48 probes with a smaller delta in samples with TP53 mutation, 
i.e. smaller differences in expression between the before and after samples for those 
genes (Figure 28). No genes were found to have a significantly higher delta in 
samples with mutated p53.      
Figure 28. SAM analysis, paired samples. SAM analysis was performed on tumor sample pairs 
collected before and after doxorubicin treatment from the same patient (n=56), which either had wild 
type (n=45 pairs) or mutated (n=11 pairs) p53. The delta values were used as input (the differences in 
expression between the before and after sample for a given patient). Two class paired analysis revealed 
48 probes having a significant difference in delta value between the wild type and the mutated p53 
samples. These probes (FDR≈0-4.2%) had a lower delta value in the samples with a mutation in TP53 
representing a smaller change in expression following doxorubicin treatment. 
For each of the 48 probes found to have a smaller delta in samples with TP53 
mutation, the average delta was calculated for the group of samples with different 
TP53 status. The genes and the average delta in addition to the absolute difference in 
delta values are shown in Table 11.  
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Table 11. The 48 probes found to have a lower delta in tumor samples collected from patients with 
TP53 mutation. For each probe, gene name, average delta value for both the TP53 wild type and 
mutated samples and the absolute difference in delta values are displayed. A positive delta value 
corresponds to an induction in expression, while a negative delta value corresponds to repression. The 
list is sorted according to gene name.  
Probe ID Gene name Average delta 
TP53 wt (n=45) 
Average delta TP53 
mutated (n=11) 
Absolute 
difference in 
delta 
A_24_P398790 C14orf102 0.58 -0.31 0.90 
A_23_P70359 C6orf59 0.66 -0.52 1.18 
A_24_P215653 CLEC14A 2.15 0.72 1.43 
A_23_P42322 COL11A2 0.41 -0.95 1.37 
A_23_P105803 FGF9 0.95 -0.92 1.87 
A_24_P59471 FLJ36840 -0.26 -1.31 1.05 
A_23_P55897 KANK2 0.37 -0.48 0.85 
A_23_P127406 KDM4D 1.31 0.35 0.97 
A_32_P100830 KIF19 1.79 -0.49 2.28 
A_24_P184937 KLHL36 0.74 0.00 0.74 
A_23_P32175 LHX6 1.45 -0.61 2.06 
A_32_P199263 LOC389831 -0.45 -1.36 0.91 
A_23_P397293 LY6K 1.01 -1.28 2.28 
A_32_P138348 LY6K 0.97 -1.18 2.15 
A_24_P392280 MCTS1 -0.19 -1.03 0.85 
A_24_P142885 PANK2 0.12 -0.75 0.87 
A_23_P71928 SH2D3C 1.75 0.68 1.07 
A_24_P101314 SHF 0.52 -0.46 0.98 
A_24_P356916 SLC13A3 0.57 -0.63 1.19 
A_24_P102151 SNRK 0.16 -0.97 1.14 
A_23_P254816 TCF15 1.24 -0.24 1.49 
A_23_P40611 TCN2 1.58 0.44 1.14 
A_23_P154566 TOX2 1.38 0.01 1.37 
A_23_P144746 ZNF454 0.86 -0.63 1.49 
A_23_P144704   -0.47 -1.44 0.97 
A_23_P385084   0.75 -0.71 1.46 
A_23_P57482   0.58 -0.61 1.18 
A_24_P128361   1.13 -0.76 1.90 
A_24_P204976   -0.01 -1.01 0.99 
A_24_P221092   -0.13 -1.12 0.99 
A_24_P247774   1.02 -0.88 1.90 
A_24_P248255   0.65 -0.64 1.30 
A_24_P367804   0.05 -1.09 1.14 
A_24_P640212   -0.43 -1.43 0.99 
A_24_P735073   -0.61 -1.58 0.97 
A_24_P753849   -0.33 -1.18 0.85 
A_24_P940615   0.20 -0.85 1.05 
A_32_P111235   -0.08 -0.89 0.81 
A_32_P113404   0.11 -1.02 1.13 
A_32_P116088   0.19 -1.17 1.36 
A_32_P139311   -0.27 -1.34 1.07 
A_32_P196287   -0.14 -1.22 1.08 
A_32_P198791   0.45 -0.91 1.36 
A_32_P5432   0.09 -1.19 1.28 
A_32_P6442   0.39 -0.41 0.80 
A_32_P73039   -0.24 -1.58 1.34 
A_32_P73580   -0.17 -1.04 0.87 
A_32_P930953   -0.14 -1.24 1.10 
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5.4.3 Ingenuity Pathway Analysis of genes differentially expressed between 
samples with wild type and mutated p53 
The genes identified by SAM analysis to have a different delta value between samples 
with wild type and mutated p53 were further investigated in IPA. First, the probe list 
with the 48 probes was processed. Un-annotated probes were updated using SOURCE 
where possible, while the probes that remained un-annotated were deleted. This 
resulted in 28 unique genes which were uploaded to IPA. The IPA analysis revealed 
information about the gene set, including molecular and cellular functions and 
transcription factors responsible for the gene expression changes (Table 12). Selecting 
a Benjamini-Hochberg threshold value of 0.05 identified 40 molecular and cellular 
functions enriched in the genes which had a lower delta value in samples with 
mutated p53. However, the majority of the functions did only have one molecule 
associated with the specific function. Therefore, another threshold was set to only 
including the functions which had 4 or more molecules involved, and they are listed 
in Table 12. No canonical pathways or tox lists were found to be significantly 
overrepresented in the genes having a smaller delta in the mutated p53 samples after 
correction.  
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Table 12. The molecular and cellular functions (a) and the five top transcription factors (b) 
overrepresented in the list of genes with a smaller delta in samples collected from patients with 
mutation in TP53. For each function, the Benjamini-Hochberg multiple testing correction p-value and 
the genes associated with the function are provided. The p-value, not corrected for multiple testing, and 
the number of target molecules are displayed for each transcription factor.   
 
5.5 Intrinsic Subclassification 
Intrinsic subclassification was performed both on the samples collected before and 
after doxorubicin therapy. Some of the samples included in this study were previously 
classified with subtype using cDNA microarrays. The classification of before samples 
was performed to evaluate if the gene expression experiment using new mRNA arrays 
would give the same or a different subtype of the samples that were previously 
classified. The classification of the after samples was performed to assess if the 
subtype of the after sample changed compared to the before sample from the same 
tumor as a result of doxorubicin therapy. 
The ‘intrinsic’ gene list described by Sørlie and colleagues containing CloneIDs were 
updated with Unigene IDs using the Stanford SOURCE Search website. A total of 
491 genes of the original 552 intrinsic genes had valid Unigene IDs. These were 
a)  Molecular and Cellular Functions overrepresented in the list of genes with a smaller delta 
in p53 mutated samples (n=28) 
Name  B-H P-value  Genes (≥4) 
Organ Morphology  1.58E-02 – 1.03E-01 FGF9, KDM4D, SH2D3C, 
COL11A2 
Tissue Development 1.58E-02 – 1.00E-01 COL11A2, FGF9, TCF15, 
LHX6, SH2D3C   
Cellular Development 1.58E-02 – 6.24E-02 COL11A2, FGF9, TCF15, 
LHX6  
Tissue Morphology 1.58E-02 – 9.85E-01 FGF9, TCF15, SH2D3C, 
MCTS1   
Small Molecule Biochemistry 2.54E-02 – 1.00E-01 SLC13A3, TCN2, PANK2, 
FGF9 
b) Top Transcription Factors overrepresented in the list of genes with a smaller delta in p53 
mutated samples (n=28) 
Transcription Regulator  P-value of overlap  Target molecules  
PAX3 6.05E-04 SNRK, FGF9, TCN2 
TOB1 6.66E-04 SNRK, TCN2 
FUBP3 9.73E-04 FGF9 
ZNF219 2.92E-03 COL11A2 
HEXIM1 6.79E-03 FGF9 
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matched with the normalized and filtered mRNA expression data for the 128 samples 
collected before and after doxorubicin treatment. In all, there were 590 genes that 
matched the intrinsic gene set because several genes had more than one probe that 
represented the same gene. The genes having more than one probe were excluded 
from the analysis, yielding a total of 239 genes with unique Unigene IDs that matched 
the intrinsic gene list. The before and after samples were classified with tumor 
subtype by calculating the Pearson correlation between each sample and the five 
centroids. The subtype of each sample was determined by using the centroid with the 
largest correlation coefficient.  
5.5.1 Subclassification of before samples using cDNA- and Agilent 44K 
microarrays 
A total of 30 before samples had previously been classified with cDNA microarrays. 
Comparing the new subtype classification of the before samples to the original 
subtype of these samples revealed that 11 of the samples were scored with a different 
subtype than the original (Figure 29). Six of the samples which were original 
classified in the HER2-enriched subgroup were scored as either luminal A or luminal 
B with the new classification. The rest of the samples with original luminal A or 
luminal B subtype were classified with the opposite luminal subtype.  
 
Figure 29. Intrinsic subclassification of samples collected before doxorubicin therapy. A total of 30 
samples collected before treatment included in this study were previously classified using cDNA 
arrays. The new subclassification performed in this study was carried out using Agilent 44K/mRNA 
arrays (n=128). Of the 30 samples previously classified, 11 samples were scored with a different 
subtype using the new arrays. The black boxes indicate the change in subclassification between the two 
arrays for the overlapping samples.  
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5.5.2 Comparison of subclassification of before and after samples 
Comparing the subclass of the before and after pairs classified with the new mRNA 
arrays, revealed that nine after samples were scored with a different subtype than the 
before sample from the same tumor (Table 13). Of the nine pairs, one sample was 
collected from a patient characterized as doxorubicin responder (PR) while the rest of 
the samples were collected from non-responders (SD/MC). In addition, when looking 
at the unsupervised cluster of all the samples included in this study, only the BC 80 
before and after sample clustered together (see Figure 19).  
Table 13. The nine before and after pairs in which the after samples were scored with another subtype 
following doxorubicin treatment compared to the before sample from the same patient. The correlation 
coefficients of the five centroids of the before (a) and after (b) sample of each pair are provided. The 
centroid with the largest correlation coefficient for each sample is indicated in red.  
 
 
 
 
 
a) Before 
Sample 
Lum A Lum B HER2-
enriched 
Basal-like Normal-like 
BC 10 0.086 0.130 -0.210 -0.172 -0.381 
BC 103 0.168 0.262 -0.270 -0.156 -0.369 
BC 106 0.184 0.289 -0.273 -0.172 -0.414 
BC 85 0.175 0.186 -0.235 -0.173 -0.374 
BC 50 0.221 0.008 -0.303 -0.254 -0.145 
BC 71 0.003 -0.004 -0.102 -0.045 -0.067 
BC 80 -0.131 0.074 -0.029 0.060 -0.285 
BC 5 -0.091 0.412 -0.184 0.083 -0.460 
BC 81 0.050 -0.139 -0.257 -0.037 0.124 
b) After 
Sample 
Lum A Lum B HER2-
enriched 
Basal-like Normal-like 
BC 10 0.159 -0.071 -0.252 -0.195 -0.069 
BC 103 0.252 0.156 -0.328 -0.212 -0.341 
BC 106 0.079 -0.071 -0.220 -0.080 0.028 
BC 85 0.174 0.157 -0.185 -0.162 -0.291 
BC 50 0.036 0.053 -0.165 -0.129 -0.232 
BC 71 -0.026 0.213 -0.036 -0.045 -0.319 
BC 80 -0.139 0.221 -0.104 0.271 -0.222 
BC 5 0.006 -0.085 -0.179 -0.048 0.010 
BC 81 -0.306 0.137 0.034 0.336 -0.183 
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6 Discussion 
This section is divided into two parts. Biological considerations regarding the results 
are discussed first, followed by a discussion concerning the methodological 
considerations.  
6.1 Gene Expression Analysis and Biological Considerations   
A discussion of the results obtained in this study is described below in the same order 
as they are presented under the result section.  
6.1.1 Gene expression pattern in tumor samples before and after doxorubicin 
treatment  
Comparing the gene expression profile in tumor samples collected pre- and post 
neoadjuvant doxorubicin treatment may give information regarding doxorubicin 
action both at the individual gene level as well as pathway based. This may further 
explore the underlying molecular mechanisms of doxorubicin cytotoxicity.  
The separation of the samples collected before and after doxorubicin treatment in the 
PCA analysis indicated an overall difference in gene expression between samples 
collected pre- and post therapy. We wanted to include both all samples and only the 
paired samples collected from the same tumor in different analyses. Including only 
the paired samples would make it possible to correct for intratumor differences to 
some degree, while including all samples would increase the power of the statistical 
analyses.  
6.1.1.1 Unsupervised clustering   
Unsupervised clustering of all the 128 experimental samples was performed to 
investigate the overall sample relations based on gene expression patterns. The cluster 
analysis by all probes did not separate the samples collected before and after 
doxorubicin therapy into two clear clusters. In other words, doxorubicin treatment 
does not overall lead to a distinct change in expression profile which can completely 
separate the samples collected from patients before and after doxorubicin treatment. 
When examining the subcluster that contained the majority of the samples, the cluster 
could be divided into three main clusters. A significant different distribution of the 
before and after samples in these clusters was revealed. The two external clusters on 
each end of the dendrogram were compromised of a majority of after samples.  
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Of the total 56 matched pairs consisting of tumor samples collected pre- and post 
therapy from the same patient, as many as 38 (67.9%) of the pairs clustered 
separately. This may indicate that doxorubicin therapy in some cases have a stronger 
impact in the gene expression profile than the molecular program of the primary 
tumor itself. But it may also point to intratumor transcriptional heterogeneity and be a 
result of sampling of different parts of the tumor. Interestingly, the majority of the 
pairs that clustered together were found in the ‘before cluster’ i.e. the cluster that 
contained the majority of the before samples. This may indicate a lower induction of 
genes after doxorubicin treatment for those pairs. 
Previous studies comparing gene expression patterns in tumor samples drawn from 
the same patient before and after therapy have shown more similarity between 
samples collected from the same patient than between samples from different patients 
collected at the same time-point (54). Perou et.al. examined the gene expression 
pattern in 20 tumor pairs collected before and after doxorubicin treatment from the 
same patient using cDNA microarrays. In all, 15 pairs (75%) were revealed to cluster 
together. A total of 15 of these tumor pairs were also included in this study. The 
clustering analysis revealed that 10 of these 15 pairs were separated using new mRNA 
arrays, while 5 pairs still clustered together. The differences in frequency of pairs 
clustering together may be that the previous study utilized fewer genes i.e.1753 to 
organize the samples based on their gene expression profile. The clustering in this 
thesis was performed using 26234 probes corresponding to 14046 unique genes. The 
higher amount of probes may detect more differences in expression, therefore 
separating more of the tumor samples drawn from the same patient. Our results from 
the clustering analysis indicates that for a subset of the samples the alterations in gene 
expression profile following treatment is high enough to separate the before and after 
samples collected from the same tumor.   
6.1.1.2 Genes differentially expressed between before and after samples  
When SAM analysis was performed to identify differentially expressed genes 
between before and after samples, a high number of probes were revealed to be up- 
and down regulated after treatment for both the unpaired and paired analysis. We used 
the probes that were differentially expressed from the unpaired comparison of before 
and after samples to cluster the 128 experimental samples. When using this subset of 
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probes, only four before and after pairs still clustered together. This indicates a greater 
separation of the samples compared to when all probes from the microarray analysis 
were used.  
We selected the genes from the SAM analysis showing the top 25% fold change to be 
further studied in pathway analyses. The genes, with the top 25% fold change, showed 
high concordance between the unpaired and paired gene lists. This may imply that 
intratumor heterogeneity is not affecting the results to a high degree when focusing on 
the genes with the highest fold change. The analysis of the list of unique genes which 
were shown to be up regulated after doxorubicin treatment are discussed first, 
followed by a discussion of the list of genes down regulated after treatment.  
6.1.1.3 Analysis of genes up regulated after therapy  
Analysis of selected up regulated genes in IPA revealed several identical functions, 
canonical pathways, transcription regulators and tox lists between the unpaired and 
paired analysis. Since the concordance between the genes having the top 25% fold 
change in the unpaired and paired gene list was high, this is a result we expected. The 
similarity implicated that either including or excluding the samples collected only 
before or after therapy from a given patient do not seem to affect the results when 
focusing on the genes with the highest fold change. Including more of the genes 
identified in the SAM analysis may have increased the difference between the 
unpaired and paired analysis, but this have to be explored in future analysis and are 
not included in this thesis.    
The three functions “cardiovascular system development and function”, “organismal 
development” and “cellular movement” found to be enriched in the list of up 
regulated genes from both analysis involved among other development of blood 
vessels, vasculogenesis, angiogenesis, migration of endothelial cells and migration of 
tumor cells. This may indicate that doxorubicin therapy influences these processes. If 
doxorubicin treatment causes cell cycle arrest due to inhibition of topoisomerase II 
and the creation of DNA breaks, the tumor may use other mechanism such as 
angiogenesis to continue to grow and proliferate. A study using a transgenic breast 
cancer model implicated that the anti-tumor activity of doxorubicin was enhanced by 
inhibiting the angiogentic signaling receptor VEGF2 (94). Doxorubicin was not 
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reported to influence tumor angiogenesis in a study focusing on chemotherapy and 
angiogenesis (95), but this should be further examined. Another study from metastatic 
breast cancer in mouse models reported that doxorubicin stimulated both motility and 
invasion of breast cancer cells by activating TGFβ, transforming growth factor β, 
signaling (96). The researchers reported that this has the potential to generate drug 
resistant cancer cells. Likewise, a study using a transgenic model for breast cancer 
metastasis showed that doxorubicin increased the level of TGFβ as well as circulating 
tumor cells (97). Among the genes with top 25% fold change up regulated after 
therapy in our study, MMP2, matrix metallopeptidase 2, was involved in several of 
the functions and pathways enriched within the gene lists. Matrix metallopeptidases 
are responsible for the degradation of the extracellular matrix and have been reported 
to be involved in breast cancer invasion, metastasis and tumor angiogenesis (98;99). 
Together, it can be speculated that these findings indicate that doxorubicin not only 
induce a cytotoxic effect on cancer cells, but may in addition also induce cell 
migration, invasion and angiogenesis. This is only a hypothesis so far, and further 
investigation will be needed to explore these possible functions of doxorubicin.  
Several of the canonical pathways overrepresented in the list of genes with the top 
25% fold change up regulated after therapy included immune responses such as 
pathways involved in Rheumatoid Arthritis, “complement system” and “leukocyte 
extravasation signaling”, indicating an activation of immune responses following 
treatment. Chemotherapeutic drugs have been shown to both induce immune 
responses which can promote tumor growth and responses which can lead to 
undesirable side effects (100). The biological effect of the complement system 
includes among other clearance of immune complexes and apoptotic cells. The 
cytotoxic effect of doxorubicin leading to cell death may generate cell debris that 
needs to be cleared. Likewise, the leukocyte extravasation which is the migration of 
leukocytes from blood to tissue during inflammation may be a result of the 
inflammatory response which arises in the tumor after doxorubicin treatment (101). 
The pathways “Wnt/β-catenin signaling” and “human embryonic stem cell 
pluripotency” were also found to be enriched in the list of genes up regulated after 
treatment in both the unpaired and paired analysis. Wnt/β-catenin signaling 
compromises extracellular growth factors involved in various aspects of development 
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such as cell differentiation, cell polarity and cell proliferation. Interestingly, Wnt is 
involved in controlling stem cell self-renewal and differentiation (102). The Wnt/β-
catenin pathway has been reported to be deregulated in cancer or cancer stem cells 
(102). It has also been implicated to play a role in doxorubicin chemoresistance in 
osteosarcoma and nevroblastoma tumor cells (103;104). A study of early lung 
metastasis provided a link between the Wnt signaling pathway and epithelial-
mesenchymal transition in basal-like breast cancer, involved in the metastatic cascade 
to increase cells motility (105). When inhibiting the Wnt signaling, the cancer cells 
decreased the capacity to self renew and drive tumorigenesis. The canonical pathway 
“PTEN signaling” was only found to be enriched in the gene list containing up 
regulated genes from the unpaired analysis. PTEN is a tumor suppressor phosphatase 
which regulates signalling pathways involved in cell growth, migration and apoptosis 
(106). Since PTEN signaling is overrepresented in the list of genes up regulated after 
doxorubicin treatment, this may imply that genes in the PTEN signalling pathway are 
involved in the doxorubicin induced apoptosis. A study using PTEN-null cells 
reported that apoptosis following doxorubicin treatment was decreased in the cells 
with truncated PTEN protein compared to cells expressing a functional PTEN (107). 
Interestingly, when looking more into the up regulated genes with top 25% fold 
change involved in the different functions and canonical pathways, we found several 
genes reported to have a transcriptional response to doxorubicin treatment in tumors 
such as ABCB1, ABCG2 and FGF2. ABCB1 and ABCG2 are ATP-dependent 
membrane transporters which promote drug efflux leading to decreased drug 
accumulation. Both genes have been reported to mediate drug resistance (108). 
Likewise, FGF2, fibroblast growth factor 2, have been implicated in the development 
of doxorubicin resistance (109).   
When comparing the transcription factors revealed by IPA to be overrepresented as 
gene expression regulators within the unpaired and paired gene lists, TP53 was found 
to regulate the highest number of genes within both lists. p53 plays a major role in 
DNA damage response and apoptosis (110). Mutations in p53 have previously been 
associated with resistance to doxorubicin therapy in breast cancer patients (111). A 
study of  p53 knockout cells showed that these cells are more resistant to doxorubicin 
than cells having a wild type p53 (112). Likewise, a study of doxorubicin action in 
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mice models revealed that mice lacking p53 had a growth delay when treated with 
doxorubicin, indicating that doxorubicin efficacy is modulated by p53 (113).   
Other transcription factors such as SP1, SP3 and KLF2 were also found to regulate a 
high number of target genes found in both the unpaired and paired lists containing up 
regulated genes. SP1 and SP3 are members of the Specificity Protein/Kruppel-like 
factor transcriptions regulators that have roles in various cellular processes. SP1 and 
SP3 have been associated with tumorigenesis, and the expression of both genes  have 
been found to be increased in cancer cells (114). KLF2 is a member of Kruppel-like 
factor proteins that have tumor suppressor functions and are reported to inhibit 
proliferation, migration and angiogenesis while inducing apoptosis and adhesion 
(115). KLF2 expression has been shown to be reduced in many malignancies such as 
ovarian cancer (116). Additionally, it has been reported to be up regulated in a 
doxorubicin resistant osteosarcoma cell line and therefore indicated to be involved in 
a drug resistant phenotype (117).  
During the IPA analysis we also investigated the tox lists which were found to be 
enriched in the genes with top 25% fold change up regulated after doxorubicin 
therapy for both the unpaired and paired analysis. The tox lists were compromised of 
functions involved in cardiotoxicity, hepatotoxicity and nephrotoxicity. The main 
adverse effect of doxorubicin is known to be irreversible cardiotoxicity often leading 
to degenerative cardiomyopathy/heart failure (118). Many mechanisms of the 
cardiotoxicity induced by doxorubicin have been proposed and studied. Several 
studies have implicated that oxidative stress involving production of reactive oxygen 
species (ROS) during doxorubicin metabolism causes the doxorubicin-induced 
cardiotoxicity (119). Interestingly, “oxidative stress” was one of the tox list found to 
be enriched in the paired gene list from the comparison of pre- and post doxorubicin 
samples. The other tox functions involving liver and kidney toxicity may be a result 
of the pharmacokinetics of doxorubicin. The biotransformation of doxorubicin occurs 
primarily in the liver, and doxorubicin clearance is mediated by bile excretion and 
renal clearance (120). An important consideration regarding the analysis of the tox list 
enriched after doxorubicin treatment is that we have only measured the gene 
expression in tumor tissue and not in heart, liver or kidney tissue. However, since 
doxorubicin is administered systemic we assume that the treatment effects on gene 
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expression are similar in other tissues such as the heart but this would have to be 
confirmed e.g. in animal models.  
6.1.1.4 Analysis of genes down regulated after therapy  
The genes with the top 25% fold change found to be down regulated following 
therapy for the unpaired and paired analysis were uploaded to IPA. The cellular and 
molecular function “RNA post-transcriptional modification” was revealed by IPA to 
be enriched in the list of genes down regulated after treatment for both the unpaired 
and paired analysis. This pathway involves among other RNA- and mRNA processing 
and RNA- and mRNA splicing. In concordance with our results, a study where 
doxorubicin-induced gene expression changes in human breast cancers were 
examined reported that the down regulated genes were involved in among other RNA 
splicing, RNA processing, mRNA processing and mRNA metabolism (121). When 
looking at the canonical pathways found to be enriched in the list of genes down 
regulated after doxorubicin therapy only “EIF2 signaling” was found to be 
overrepresented within the unpaired and paired gene lists. EIFs are eukaryotic 
translation initiations factors involved in mRNA translation (122). These findings 
suggest that tumors alter processes involved in RNA/mRNA processing and 
metabolism in addition to protein synthesis in general after doxorubicin exposure, 
maybe to focus on other mechanisms more important for cell survival. 
The HNF4A transcription factor regulated the highest number of targets genes within 
the unpaired as well as the paired gene lists. This transcription factor is involved in 
hepatocyte differentiation, and its loss has been associated with hepatocellular 
carcinoma development (123). The transcription factor MYCN regulated also a high 
number of the genes down regulated after doxorubicin therapy. MYCN controls 
numerous cellular processes such as cell growth and proliferation, cell-cycle 
progression, transcription, differentiation, apoptosis and cell motility (124). It is 
frequently amplified in neuroblastomas and MYCN over expression have been found 
in breast carcinomas (125;126). However, neither of these transcription factors have 
previously been connected to doxorubicin treatment.  
All together, our results implicates that the gene expression in tumor is altered as a 
result of doxorubicin treatment. Several genes were found to be up- and down 
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regulated following treatment. However, we cannot exclude the possibility that some 
of the differences in mRNA expression between the before and after samples in the 
paired analysis is a result of different clones collected before and after therapy from 
the same tumor. It is known that breast cancer is a highly heterogeneous disease, and 
the collection of distinct clones may have an effect on the gene expression analysis.  
6.1.2 Gene expression pattern and response to therapy 
The gene expression pattern in samples collected from patients characterized as 
responders (PR) and non-responders (SD/MC) to doxorubicin were examined with the 
aim to identify a predictive profile which could be used to tailor the treatment for each 
patient. Before the gene expression profile of the samples in the two response 
categories was examined, we investigated the association between clinical parameters 
such as ER status, grade and TP53 mutations status and doxorubicin response. ER 
status of the samples collected after therapy was found to be associated with response. 
This is in agreement with a study of breast cancer response to neoadjuvant 
anthracycline-based chemotherapy that reported that ER negativity was correlated 
with better response (127). However, this connection was functionally unexplained by 
the authors.  
PCA analysis performed on samples collected from the responder and non-responder 
patients did not discriminate the samples in the two response groups, indicating an 
overall gene expression similarity. When SAM analysis was performed on the before 
samples, the after samples and on the delta expression values no significant genes 
were found to be differentially expressed between the two response groups. In 
addition, when only the probes revealed to be differentially expressed by SAM 
analysis of before and after samples were used no genes were found to be 
differentially expressed between doxorubicin responders and non-responders. We 
then tried a different approach by using gene set enrichment analysis to detect 
differences in gene expression of whole gene sets, but no differences were observed 
between the two response groups for any gene set.  
Since p53 has been connected to doxorubicin resistance, we selected p53 target genes 
found in the IPA analysis of paired before and after samples and evaluated the 
connection between these genes and response to doxorubicin. Performing SAM 
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analysis of these genes only, revealed several genes up regulated in before and after 
samples collected from patients characterized as having a partial response to 
doxorubicin. By using delta expression values several genes were found to have a 
higher delta in samples from doxorubicin responders, indicating an induction in 
expression of those genes. The up regulated genes from the analysis of after samples 
had a higher false discovery rate, we therefore chose to focus on the genes revealed to 
be connected to response from the analysis of before samples and delta values. Some 
of the genes are discussed below.  
CTGF, connective tissue growth factor, encodes an extracellular matrix-associated 
signaling molecule and has been shown to promote endothelial cell growth, migration, 
adhesion and survival (128). There is also strong evidence for that that this protein is 
involved in angiogenesis, a study of breast cancer cells showed that connective tissue 
growth factors including CTGF were involved in breast cancer angiogenesis (129). A 
study of neoadjuvant doxorubicin and cyclophosphamide treatment of breast cancer 
patients revealed that CTGF was more expressed in samples collected after than 
before treatment, and it was implicated that this gene could be connected to drug 
resistance (130). ITGB4 encodes integrin, beta 4, a member of the integrin family 
transmembrane receptors which mediates cell-matrix or cell-cell adhesion in addition 
to transducing signals that regulates gene expression and cell growth. ITG4B has been 
proposed to be involved in carcinoma progression by regulating the migration, 
invasion and survival of carcinoma cells (131). This gene has also been found to 
promote tumor angiogenesis in a mouse model (132). IGF1 was found to have a 
higher delta in the samples collected from patients assessed with partial response to 
doxorubicin. It is known to have an important function in cancer biology and has been 
reported to mediate resistance to chemotherapy (133). A study of atypical teratoid 
rhabdoid tumor cells revealed that inhibition of the IGF1 receptor sensitized the tumor 
cells to doxorubicin and cisplatin treatment (134). Another study showed that IGF1 
attenuated the response of breast cancer cells to doxorubicin by inducing proliferation 
and inhibiting apoptosis (135). The results from this study may also imply that IGF1 
is involved in response to doxorubicin treatment.  
The genes found to be up regulated in doxorubicin responders should be further 
studied in the continuation of this thesis by performing e.g. experiments in cell lines. 
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mRNA expression data from untreated and doxorubicin treated  xenograft models 
have been generated in the lab previously, and the results from this study should also 
be compared to the data from the animal models.   
It could be speculated that no prominent predictive gene expression profile was 
observed when performing SAM on the total microarray data because the tumors 
included in this study had a less effective response to doxorubicin therapy. No 
samples were characterized with a complete response. The small difference in partial 
response compared to stable disease and/or minimal change may also explain why 
predictive expression profiles were difficult to explore. Although our results indicate 
that some genes can be connected to responses to doxorubicin, this does not exclude 
that other predictive profiles exists. Several genes differentially expressed between 
patients obtaining partial response and stable disease and/or minimal change may 
become apparent when a larger number of patients can be evaluated. Additionally, 
response classifiers may be revealed when patients with more distinct responses to 
doxorubicin are included in the analysis.  
Doxorubicin pharmacology has been shown to have large inter-individual variation, 
and this may also contribute to the response (70). Both doxorubicin efficacy and 
toxicity have been implicated to be influenced by genetic variants effecting the 
expression of genes responsible for transport, metabolism and drug action. In the 
continuation of this study it would be interesting to evaluate these aspects. Whole 
genome genotyping of the germline DNA as well as tumor DNA collected from the 
patients included in this study have already been performed. The analysis from the 
genotyping experiment may elucidate the influence of genetic variation on both 
mRNA expression level and on response to doxorubicin.       
6.1.3 Gene expression pattern and TP53 mutation status 
Since p53 have been shown to modulate the activity of topoisomerase II which is the 
proposed target of doxorubicin and mutations in TP53 have been associated with 
doxorubicin resistance, we examined the differences in expression profiles between 
samples with wild type and mutated p53. The PCA analysis did not discriminate the 
samples completely, but a skewed distribution of the samples was still observed. From 
the SAM analysis 48 probes representing 28 unique, annotated genes with a lower 
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delta were revealed in the samples with p53 mutations. The lower delta indicates a 
lower induction of these genes. The IPA analysis uncovered several general molecular 
and cellular functions such as organ- and tissue morphology and cellular- and tissue 
development to be enriched within the list of 28 unique genes. Doxorubicin has 
previously been found to induce morphological changes in H9c2 myoblasts (136), but 
information connected to the finding form IPA are limited.  
The transcription factor PAX3 was found to regulate three of the genes which had a 
smaller delta in the samples with p53 mutation. PAX3 is a transcription factor 
involved in normal embryonic development, and has been implicated to be involved 
in tumorigenisis (137;138). Interestingly, PAX3 has been reported to suppress p53 
accumulation and p53-dependent apoptosis (139). The TOB1 transcription factor 
regulated two of the genes found to have a lower delta in the samples with mutation in 
p53. This transcription factor has been proposed to function as a tumor suppressor by 
inhibiting cell cycle progression in breast cancer specimens as well as breast cancer 
cell lines, therefore suppressing tumorigenisis (140). However, the link between 
PAX3 and TOB1 to p53 mutations and the effect of doxorubicin will require further 
analyses. It should be clarified that the results from the gene expression analysis 
should be interpreted with cautions because only a few samples had a mutated p53 
and few genes were uploaded to IPA, decreasing the power of the analysis. A better 
insight into the role of p53 mutations and effect of doxorubicin may become apparent 
if more patients with a mutation in TP53 were included in the analysis.     
6.1.4 Subclassification 
The subclassification of the tumor samples included in this study was performed by 
using 239 unique genes from the ‘intrinsic’ gene list provided by Sørlie and 
colleagues (92). The intrinsic gene list divided the breast cancer samples into five 
subgroups: luminal A, luminal B, HER2-enriched, basal-like and normal-like. In all, 
30 of the before samples included in this study had previously been classified using 
cDNA microarrays. When comparing the subclass of the same samples, 11 samples 
changed subtype classification. Of the six samples assessed as HER2-enriched 
subtype in the previously characterization, all obtained another subtype with the new 
classification. It would be difficult to conclude if this is a result of the new mRNA 
arrays which have higher resolutions than the old cDNA arrays, if the isolation of new 
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mRNA give another representation of the phenotype of a heterogeneous tumor or if 
this is due to the fact that only a proportion of the intrinsic genes were used in the re-
classification.  
Clonal selection during cancer evolution and also during cancer therapy have recently 
been implicated to exist (68). One of the main challenges in cancer treatment is that 
some cells escape therapy. In order to evaluate if doxorubicin has a positive selection 
of certain clones, we compared the subclass of the before and after samples from the 
same patient. This revealed that nine of the after samples were scored with a different 
subclass than the before sample. Four pairs (BC 10, BC 103, BC 85 and BC 81) had a 
high correlation coefficient indicating a strong change in the subclass. Of these pairs, 
three changed subtype from luminal B to luminal A and one changed from normal-
like to basal-like following doxorubicin treatment. The change from luminal B to 
luminal A subtype may indicate an reduction of proliferation after treatment, which 
may be connected to a more favorable outcome (141). In contrast, the change from 
normal-like to basal-like is possible indicating a more aggressive phenotype following 
therapy (142). Of the nine pairs that changed subtype after doxorubicin therapy, all 
except from one pair was collected from non-responders (SD/MC). These 
observations may also, as discussed above, be a result of using a subset of the original 
intrinsic gene list. Additionally, the correlation coefficient of either the before or the 
after sample of five pairs was below 0.1, which is very low and the results should 
therefore be interpreted with caution for these.  
To increase the confidence in the subclassification it would be important to increase 
the number of probes used for the correlation analysis. To address the problem of 
replicate probes, we could have used the average of the expression of the replicate 
probes. This would only be possible if the different probes showed the same trends 
with regards to expression. Another option is to blast the sequences of the original 
CloneIDs for the intrinsic genes to find the exact location of the probes and include 
the probes from our data set that are closest to this position. Both alternatives would 
have increased the number of intrinsic genes included in the classification, giving the 
classification a stronger power. The problem with both alternatives is that the 
included probes will still be an approximation for the original clones. Because of time 
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limitations neither alternatives were prioritized in this study but should be performed 
in the continuation of the project.    
6.2 Gene Expression Analysis and Methodological Considerations  
The methodological considerations regarding the gene expression analysis are 
described below.  
6.2.1 Patient samples and RNA quality control 
The tumor samples used in this thesis were collected previously for other studies. The 
RNA from the samples was isolated using Trizol and RNeasy minikit from Qiagen 
and stored at -80 ºC. Information regarding the RNA quantity existed from previous 
measurements. For those samples that were listed with very high concentrations, the 
quantity was measured again by NanoDrop ND-1000 UV-VIS Spectrophotometer 
(Thermo Scientific, Wilmington, Delaware, USA) because we speculated that these 
values were not reliable. RNA to be used in the gene expression microarray analysis 
was subtracted from the stock solutions and a dilution of 40 ng RNA was made for 
each sample. For the RNA samples included in this study, only a minority were 
reported with a RIN value. The quality of the samples was assessed by Agilent 2100 
Bioanalyzer (Agilent Technologies, Santa Clara, California, USA) to ensure high 
quality RNA. However, the amount of RNA in the stock solution was low for many 
samples and RNA assessment was therefore only performed on a selection of the 
samples. Because RNA from only a subset of the samples had been quality assessed, 
we cannot exclude the possibility that some effects may be related to sample quality. 
However, since the generated cRNA in the gene expression procedure are quantified 
using NanoDrop ND-1000 UV-VIS Spectrophotometer before the samples are 
hybridized to the arrays, this step will reveal samples of low quality. Of the total 131 
samples included in this study, two samples had very low Cy3 specific activity after 
the amplification and labelling phase. These samples were therefore excluded from 
the hybridization step. Additionally, some of the samples had a lower cRNA 
concentration or Cy3 specific activity than recommended in the protocol from the 
gene expression experiment after the amplification step. However, these samples were 
accepted with good quality in additional quality controls performed as a part of the 
array scoring and post-wet lab analysis.   
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6.2.2 Technical variability and data quality control 
Gene expression microarray experiment is a sensitive method, and technical 
variability during the lab procedure can influence the outcome. It is therefore 
important to minimize the sources of the technical variability. The variability can be a 
result of e.g. differences in hybridization or dissimilarities between microarrays (batch 
effects). During the microarray experiment performed in this study, the same batch of 
chemicals was used for the all the samples on each array. In addition, the experiment 
was performed in a time interval of two months by only two persons. The before and 
after samples and the samples in the different response categories were distributed on 
all the microarrays to minimize the probability of batch effects. The Agilent 
Technologies 4x44K Whole Human Genome microarrays used in this study contains 
a number of control probes which are utilized to monitor the experiment workflow.  
For each microarray a quality report summarizing the experiment was generated and 
evaluated. A few samples did not pass the quality control the first time for several 
technical reasons (such as low hybridization of the positive controls), and the 
experiment was repeated for these samples. All samples included in this thesis passed 
the quality control. Taken together, we concluded that the microarray data was of 
good quality. 
After the mRNA expression analysis data were extracted from the scanned images 
using the Feature Extraction software. The data were then uploaded to GeneSpring 
GX, in this process the data were automatically log2 transformed. The data were 
further normalized using 50% percentile shift. 50% percentile normalization was 
chosen because it aligns the sub-arrays by their median expression value, and do not 
scale all the expression intensities such as e.g. quantile normalization does. We 
therefore speculated that smaller differences in expression levels will be remained to a 
higher extent with percentile normalization compared to quantile normalization. 
Quantile normalization is a more strict normalization method, and the differences in 
expression revealed by further analysis may therefore be even more reliable. On the 
other hand, genes with smaller differences in expression may still have important 
biological functions and with this in mind we decided to normalize the data by 50% 
percentile normalization.     
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Principle Component Analysis (PCA) was performed to assess sample uniformity and 
quality in GeneSpring GX. Of the original 129 included samples, one was revealed to 
be an outlier. Going back to the quality control report for this sample, it was detected 
that the histogram of the signal intensities for this sample was different than for the 
other samples. In addition, when an unsupervised cluster of all the experimental 
samples was generated, the sample clustered entirely by itself. Based on these 
findings, the sample was discarded from further statistical analyses. The quality 
control on probes was also performed in GeneSpring GX. The probes were first 
filtered by expression, where a lower cut-off was set to 10% and a higher cut-off was 
set to 100%. Probes which were expressed less than 10% were therefore discarded 
because we concluded that probes with such low intensities could be noise or 
background. The probes were then filtered by flags, where probes flagged as 
‘compromised’ (non-uniform, saturated and population outliers) were omitted from 
further analysis. We chose to include the flag call named ‘not detected’ (non-positive, 
non-significant and below background) because by removing the probes less than 
10% expressed we expected the non-positive, non-significant and below background 
probes to also be removed from the probe list. It could be speculated that this may 
have resulted in that some probes with low expression were included in the further 
statistical analyses. In spite of this, the thresholds that we chose later in the analyses 
(e.g. only selected the genes with highest fold change etc.) will likely exclude these 
probes.  
6.2.3 Statistical analysis and bioinformatics 
mRNA expression experiments using microarrays generates a large amount of data 
and requires statistical- and bioinformatic analytic tools that can tolerate this 
extensive amount. Another challenge is the multiple testing problem which arises 
when many independent statistical tests are performed on the same data set.  
Unsupervised clustering was performed in R because of the number of probes 
extended 26000 and clustering of this high amount of probes was difficult to perform 
in e.g. GeneSpring GX or J-Express. The unsupervised clustering was performed with 
all probes and without dividing the dataset into subgroups. Given that gene expression 
data following the log2 transformation are normally distributed and that we wanted 
the closeness of the samples in the cluster to be calculated based on trends and not on 
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magnitude, we chose Pearson correlation as the distance metric. The average linkage 
method was chosen because we evaluated that the most appropriate way to calculate 
the distance in the cluster was to use the average distance between all pairs (not the 
e.g. smallest or the biggest distance as for single and complete linkage method, 
respectively).         
To investigate if genes were differentially expressed between tumor samples divided 
into groups based on experimental condition (e.g. before and after samples, 
doxorubicin responders- and non-responders) Significance Analysis of Microarrays 
(SAM) was performed. SAM was selected because of its capacity to handle large data 
sets. In addition, SAM provides a delta parameter which can be used to choose the 
threshold for significance based on the false discovery rate (FDR). This makes the 
results from SAM more reliable because they are corrected for multiple testing. To 
confirm the results from the SAM analysis we selected a few probes which were 
shown to be differentially expressed between two groups for further investigation in 
IMB SPSS Statistics 18. One-Way ANOVA revealed a significant difference in mean 
expression between the before and after samples for the selected genes. This led us to 
the conclusion that the results from SAM were trustworthy.    
A large number of probes were shown to be differentially expressed when comparing 
samples collected before and after doxorubicin treatment by SAM analysis (>6000). 
We decided therefore to only include the probes which had the largest fold change, 
i.e. top 25%, for pathway based investigation. Additionally, we evaluated that the 
probes having the highest fold change (i.e. the probes showing the largest difference 
in expression between the before and after samples) were most interesting to examine 
first. However, for further analysis on this material it would be interesting to include 
all the differentially expressed probes to evaluate what effect this would have on the 
results.  
Ingenuity Pathway Analysis (IPA) was chosen for the pathway analyses. All genes are 
weighted equal in the analysis, and a Fisher’s Exact p-value are displayed as a default 
p-value. In order to correct for the multiple testing issue, we selected a Benjamini-
Hochberg p-value which is corrected for multiple testing for the molecular and 
cellular functions, canonical pathways and tox list provided from the IPA analyses.  
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We selected the statistical and bioinformatic methods based on the ones we evaluated 
to be most correct for this experiment. It should however be noted that the different 
pre-processing methods and statistical analyses available may have an influence on 
the final outcome of microarray analysis in general. Interesting results from large 
scale microarray experiments should be validated by e.g. quantitative RT-PCR. 
Additionally, gene expression experiments measures only the abundance of the 
different mRNA molecules in the cells and will not necessarily correlate to the protein 
level. To increase the power of the results obtained in this study, investigation of other 
biological levels such as protein abundance should be performed in e.g. cell lines.   
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7 Conclusions and Future Perspectives  
Here the mRNA expression changes following doxorubicin exposure have been 
investigated in a panel of samples collected from breast cancer patients before and 
after treatment with doxorubicin. The goal has been to shed light on the molecular 
biology underlying the tumor response to doxorubicin by identifying genes and 
pathways affected by the therapy. Doxorubicin was found to be involved in numerous 
cellular processes when examining the genes up- and down regulated after treatment. 
Some pathways were thought to serve for its anticancer effect, such as PTEN 
signalling and the involvement of p53 in DNA damage responses. In contrast, other 
mechanisms such as cell movement and angiogenesis may have the opposite effect on 
tumor cells causing the cells to continue to grow and invade. Mechanisms enriched  
within the down regulated gene list such as RNA processing and splicing in addition 
to protein translation may imply that doxorubicin induced damage causes the cells to 
focus on more important processes for survival, such as DNA repair following 
treatment. TP53 was shown to regulate the highest number of molecules within the 
list of up regulated genes, and several genes were found to have a smaller change in 
expression in samples with TP53 mutations. These findings support the involvement 
of TP53 in doxorubicin response.  
The genes found to be significantly differentially expressed between samples 
collected from doxorubicin responders compared to non-responders may serve as 
biomarkers for doxorubicin response. These genes may be important to identify the 
patients that will benefit from doxorubicin therapy and those that will not.  
The alterations in gene expression profile between samples collected before and after 
therapy revealed in this study may contribute to obtaining a better insight into the 
underlying molecular mechanisms of doxorubicin antitumor activity.  Additionally, 
the genes found to be differentially expressed between doxorubicin responders and 
non-responders may be a step forward in the direction to individualize doxorubicin 
treatment.  
Further evaluations of the genes and pathways found to be altered following 
doxorubicin treatment should be performed to support the finding in this study. In the 
continuation of this thesis the entire gene list containing genes found to be 
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significantly differentially expressed should be studied, and not only the genes 
showing the highest fold change. Microarray data from cell lines and mouse models 
untreated and treated with doxorubicin exists, and this should be compared to our 
results. To evaluate the importance for the genes found to be involved in doxorubicin 
response, experiments in cell lines using miRNA/siRNA could be performed to 
evaluate the viability of the cells after these genes are inhibited.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
95 
 
References 
 
 (1)  World Health Organization (2012), Cancer mortality and morbidity [online]. Available from: 
http://www.who.int/gho/ncd/mortality_morbidity/cancer/en/index.html, [Downloaded 
12.03.2012].  
 
 (2)  International Agency for Research on Cancer (IARC) (2010), GLOBOCAN 2008 [online].  
Available from: http://globocan.iarc.fr/ [Downloaded 15.03.2012].  
 
 (3)  Kreftregisteret (2011), Kreftstatistikk for 2009 [online]. Available from: 
http://kreftregisteret.no/no/registrene/kreftstatistikk/ [Downloaded 15.03.2012].  
 
 (4)  Balmain A, Gray J, Ponder B. The genetics and genomics of cancer. Nat Genet 2003 
March;33 Suppl:238-44.:238-44. 
 (5)  Hamilton JP. Epigenetics: principles and practice. Dig Dis 2011;29(2):130-5. 
 (6)  Alberts B, Johnson A, Lewis J, Raff M, Roberts K, Walter P. Molecular Biology of THE 
CELL. 5th ed. Garland Science; 2008. 
 (7)  Polyak K. Breast cancer: origins and evolution. J Clin Invest 2007 November;117(11):3155-
63. 
 (8)  Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011 March 
4;144(5):646-74. 
 (9)  Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000 January 7;100(1):57-70. 
 (10)  Korkaya H, Liu S, Wicha MS. Breast cancer stem cells, cytokine networks, and the tumor 
microenvironment. J Clin Invest 2011 October;121(10):3804-9. 
 (11)  Spano D, Zollo M. Tumor microenvironment: a main actor in the metastasis process. Clin Exp 
Metastasis 2012 April;29(4):381-95. 
 (12)  Medina D. The mammary gland: a unique organ for the study of development and 
tumorigenesis. J Mammary Gland Biol Neoplasia 1996 January;1(1):5-19. 
 (13)  Ramsay DT, Kent JC, Hartmann RA, Hartmann PE. Anatomy of the lactating human breast 
redefined with ultrasound imaging. J Anat 2005 June;206(6):525-34. 
 (14)  Vargo-Gogola T, Rosen JM. Modelling breast cancer: one size does not fit all. Nat Rev 
Cancer 2007 September;7(9):659-72. 
 (15)  BREASTCANCER.ORG (2012), Image-Breast Anatomy [online]. Available from: 
http://www.breastcancer.org/symptoms/understand_bc/what_is_bc.jsp [Downloaded 
25.03.2012].  
 
 (16)  McNally S, Martin F. Molecular regulators of pubertal mammary gland development. Ann 
Med 2011 May;43(3):212-34. 
 (17)  Howard BA, Gusterson BA. Human breast development. J Mammary Gland Biol Neoplasia 
2000 April;5(2):119-37. 
96 
 
 (18)  Stingl J. Estrogen and progesterone in normal mammary gland development and in cancer. 
Horm Cancer 2011 April;2(2):85-90. 
 (19)  World Health Organization. Classification of Tumours, Pathology and Genetics of Tumours of 
the Breast and Female Genital Organs. Third ed. International Agency for Research on 
Cancer (IARC); 2003. 
 (20)  Harris JR, Lippmann ME, Morrow M, Osborne CK. Diseases of the Breast. Second ed. 
Philadelphia: Lippincott Willams & Wilkins; 2000. 
 (21)  Ernster VL, Ballard-Barbash R, Barlow WE, Zheng Y, Weaver DL, Cutter G et al. Detection 
of ductal carcinoma in situ in women undergoing screening mammography. J Natl Cancer 
Inst 2002 October 16;94(20):1546-54. 
 (22)  Polyak K. Is breast tumor progression really linear? Clin Cancer Res 2008 January 
15;14(2):339-41. 
 (23)  Chin K, de Solorzano CO, Knowles D, Jones A, Chou W, Rodriguez EG et al. In situ analyses 
of genome instability in breast cancer. Nat Genet 2004 September;36(9):984-8. 
 (24)  Schnitt SJ. Molecular biology of breast tumor progression: a view from the other side. Int J 
Surg Pathol 2010 June;18(3 Suppl):170S-3S. 
 (25)  Peto J, Collins N, Barfoot R, Seal S, Warren W, Rahman N et al. Prevalence of BRCA1 and 
BRCA2 gene mutations in patients with early-onset breast cancer. J Natl Cancer Inst 1999 
June 2;91(11):943-9. 
 (26)  Peto J, Mack TM. High constant incidence in twins and other relatives of women with breast 
cancer. Nat Genet 2000 December;26(4):411-4. 
 (27)  Stratton MR, Rahman N. The emerging landscape of breast cancer susceptibility. Nat Genet 
2008 January;40(1):17-22. 
 (28)  Walsh T, King MC. Ten genes for inherited breast cancer. Cancer Cell 2007 
February;11(2):103-5. 
 (29)  Thomas G, Jacobs KB, Kraft P, Yeager M, Wacholder S, Cox DG et al. A multistage genome-
wide association study in breast cancer identifies two new risk alleles at 1p11.2 and 14q24.1 
(RAD51L1). Nat Genet 2009 May;41(5):579-84. 
 (30)  Wang DG, Fan JB, Siao CJ, Berno A, Young P, Sapolsky R et al. Large-scale identification, 
mapping, and genotyping of single-nucleotide polymorphisms in the human genome. Science 
1998 May 15;280(5366):1077-82. 
 (31)  Brookes AJ. The essence of SNPs. Gene 1999 July 8;234(2):177-86. 
 (32)  Foulkes WD. Inherited susceptibility to common cancers. N Engl J Med 2008 November 
13;359(20):2143-53. 
 (33)  McPherson K, Steel CM, Dixon JM. ABC of breast diseases. Breast cancer-epidemiology, risk 
factors, and genetics. BMJ 2000 September 9;321(7261):624-8. 
 (34)  Russnes HG, Navin N, Hicks J, Borresen-Dale AL. Insight into the heterogeneity of breast 
cancer through next-generation sequencing. J Clin Invest 2011 October 3;121(10):3810-8. 
 (35)  Rakha EA, Reis-Filho JS, Baehner F, Dabbs DJ, Decker T, Eusebi V et al. Breast cancer 
prognostic classification in the molecular era: the role of histological grade. Breast Cancer 
Res 2010;12(4):207. 
97 
 
 (36)  Ignatiadis M, Sotiriou C. Understanding the molecular basis of histologic grade. Pathobiology 
2008;75(2):104-11. 
 (37)  Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of 
histological grade in breast cancer: experience from a large study with long-term follow-up. 
Histopathology 1991 November;19(5):403-10. 
 (38)  Singletary SE, Connolly JL. Breast cancer staging: working with the sixth edition of the AJCC 
Cancer Staging Manual. CA Cancer J Clin 2006 January;56(1):37-47. 
 (39)  Singletary SE, Allred C, Ashley P, Bassett LW, Berry D, Bland KI et al. Revision of the 
American Joint Committee on Cancer staging system for breast cancer. J Clin Oncol 2002 
September 1;20(17):3628-36. 
 (40)  Bland KI, Menck HR, Scott-Conner CE, Morrow M, Winchester DJ, Winchester DP. The 
National Cancer Data Base 10-year survey of breast carcinoma treatment at hospitals in the 
United States. Cancer 1998 September 15;83(6):1262-73. 
 (41)  Bertos NR, Park M. Breast cancer - one term, many entities? J Clin Invest 2011 
October;121(10):3789-96. 
 (42)  Welboren WJ, Sweep FC, Span PN, Stunnenberg HG. Genomic actions of estrogen receptor 
alpha: what are the targets and how are they regulated? Endocr Relat Cancer 2009 
December;16(4):1073-89. 
 (43)  Jordan VC, Brodie AM. Development and evolution of therapies targeted to the estrogen 
receptor for the treatment and prevention of breast cancer. Steroids 2007 January;72(1):7-25. 
 (44)  Patel RR, Sharma CG, Jordan VC. Optimizing the antihormonal treatment and prevention of 
breast cancer. Breast Cancer 2007;14(2):113-22. 
 (45)  Bartlett JM, Brookes CL, Robson T, van de Velde CJ, Billingham LJ, Campbell FM et al. 
Estrogen receptor and progesterone receptor as predictive biomarkers of response to endocrine 
therapy: a prospectively powered pathology study in the Tamoxifen and Exemestane Adjuvant 
Multinational trial. J Clin Oncol 2011 April;20;29(12):1531-8. 
 (46)  Dunnwald LK, Rossing MA, Li CI. Hormone receptor status, tumor characteristics, and 
prognosis: a prospective cohort of breast cancer patients. Breast Cancer Res 2007;9(1):R6. 
 (47)  Andrulis IL, Bull SB, Blackstein ME, Sutherland D, Mak C, Sidlofsky S et al. neu/erbB-2 
amplification identifies a poor-prognosis group of women with node-negative breast cancer. 
Toronto Breast Cancer Study Group. J Clin Oncol 1998 April;16(4):1340-9. 
 (48)  Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: 
correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 
1987 January 9;235(4785):177-82. 
 (49)  Sjogren S, Inganas M, Lindgren A, Holmberg L, Bergh J. Prognostic and predictive value of 
c-erbB-2 overexpression in primary breast cancer, alone and in combination with other 
prognostic markers. J Clin Oncol 1998 February;16(2):462-9. 
 (50)  Junttila TT, Akita RW, Parsons K, Fields C, Lewis Phillips GD, Friedman LS et al. Ligand-
independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively 
inhibited by the PI3K inhibitor GDC-0941. Cancer Cell 2009 May 5;15(5):429-40. 
 (51)  Murphy CG, Fornier M. HER2-positive breast cancer: beyond trastuzumab. Oncology 
(Williston Park) 2010 April 30;24(5):410-5. 
98 
 
 (52)  Nishimura R, Arima N. Is triple negative a prognostic factor in breast cancer? Breast Cancer 
2008;15(4):303-8. 
 (53)  Reis-Filho JS, Weigelt B, Fumagalli D, Sotiriou C. Molecular profiling: moving away from 
tumor philately. Sci Transl Med 2010 September 1;2(47):47ps43. 
 (54)  Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA et al. Molecular portraits 
of human breast tumours. Nature 2000 August 17;406(6797):747-52. 
 (55)  Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H et al. Gene expression patterns 
of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad 
Sci U S A 2001 September 11;98(19):10869-74. 
 (56)  Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, Conway K et al. Race, breast 
cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 2006 June 
7;295(21):2492-502. 
 (57)  Prat A, Perou CM. Deconstructing the molecular portraits of breast cancer. Molecular 
Oncology 2010 November 24;5:5-23. 
 (58)  Herschkowitz JI, Simin K, Weigman VJ, Mikaelian I, Usary J, Hu Z et al. Identification of 
conserved gene expression features between murine mammary carcinoma models and human 
breast tumors. Genome Biol 2007;8(5):R76. 
 (59)  Reis-Filho JS, Pusztai L. Gene expression profiling in breast cancer: classification, 
prognostication, and prediction. Lancet 2011 November;19;378(9805):1812-23. 
 (60)  de SF, Bender R, Glas A, Rutgers E. Gene expression profiling: decoding breast cancer. Surg 
Oncol 2009 December;18(4):366-78. 
 (61)  van 't Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, Mao M et al. Gene expression 
profiling predicts clinical outcome of breast cancer. Nature 2002 January 31;415(6871):530-6. 
 (62)  Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M et al. A multigene assay to predict 
recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004 December 
30;351(27):2817-26. 
 (63)  Norsk Bryst Cancer Gruppe (NBCG) (2011), Blåboka [online]. Available from: 
http://nbcg.no/nbcg.blaaboka.html [Downloaded 02.04.2012].  
 
 (64)  Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and 
hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of 
the randomised trials. Lancet 2005 May 14;365(9472):1687-717. 
 (65)  D'Souza N, Darmanin G, Fedorowicz Z. Immediate versus delayed reconstruction following 
surgery for breast cancer. Cochrane Database Syst Rev 2011 July 6;(7):CD008674. 
 (66)  Helleday T, Petermann E, Lundin C, Hodgson B, Sharma RA. DNA repair pathways as targets 
for cancer therapy. Nat Rev Cancer 2008 March;8(3):193-204. 
 (67)  Jain P, Alahari SK. Breast cancer stem cells: a new challenge for breast cancer treatment. 
Front Biosci 2011 January 1;16:1824-32.:1824-32. 
 (68)  Greaves M, Maley CC. Clonal evolution in cancer. Nature 2012 January 18;481(7381):306-
13. 
99 
 
 (69)  Weiss RB. The anthracyclines: will we ever find a better doxorubicin? Semin Oncol 1992 
December;19(6):670-86. 
 (70)  Jamieson D, Boddy AV. Pharmacogenetics of genes across the doxorubicin pathway. Expert 
Opin Drug Metab Toxicol 2011 October;7(10):1201-10. 
 (71)  Gewirtz DA. A critical evaluation of the mechanisms of action proposed for the antitumor 
effects of the anthracycline antibiotics adriamycin and daunorubicin. Biochem Pharmacol 
1999 April 1;57(7):727-41. 
 (72)  DrugBank (2012), Doxorubicin [online]. Available from: 
http://www.drugbank.ca/drugs/DB00997 [Downloaded 02.04.2012].  
 
 (73)  Wang JC. Cellular roles of DNA topoisomerases: a molecular perspective. Nat Rev Mol Cell 
Biol 2002 June;3(6):430-40. 
 (74)  Attia SM. Comparative aneugenicity of doxorubicin and its derivative idarubicin using 
fluorescence in situ hybridization techniques. Mutat Res 2011 October 1;715(1-2):79-87. 
 (75)  PharmGKB (2012), Doxorubicin Pathway [online]. Available from: 
http://www.pharmgkb.org/pathway/PA165292163 [Downloaded 03.04.2012].  
 
 (76)  Minotti G, Menna P, Salvatorelli E, Cairo G, Gianni L. Anthracyclines: molecular advances 
and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev 
2004 June;56(2):185-229. 
 (77)  Kaye S, Merry S. Tumour cell resistance to anthracyclines--a review. Cancer Chemother 
Pharmacol 1985;14(2):96-103. 
 (78)  Geisler S, Lonning PE, Aas T, Johnsen H, Fluge O, Haugen DF et al. Influence of TP53 gene 
alterations and c-erbB-2 expression on the response to treatment with doxorubicin in locally 
advanced breast cancer. Cancer Res 2001 March 15;61(6):2505-12. 
 (79)  Hayward JL, Carbone PP, Heusen JC, Kumaoka S, Segaloff A, Rubens RD. Assessment of 
response to therapy in advanced breast cancer. Br J Cancer 1977 March;35(3):292-8. 
 (80)  Butte A. The use and analysis of microarray data. Nat Rev Drug Discov 2002 
December;1(12):951-60. 
 (81)  Stears RL, Martinsky T, Schena M. Trends in microarray analysis. Nat Med 2003 
January;9(1):140-5. 
 (82)  Agilent Technologies Inc. One-Color Microarray-Based Gene Expression Analaysis, Low 
Input Quick Amp Labeling. Version 6.5. 2010.  
 
 (83)  Agilent Technologies Inc. Agilent One Color RNA Spike-In Kit. First edition. 2005.  
 
 (84)  Agilent Technologies Inc. Agilent microarray hybridization chamber user guide. Version 2.0. 
2006.  
 
 (85)  Agilent Technologies Inc. Agilent G2565CA Microarray Scanner System (Scan Control 
Software 8.5) User Guide.  2010.  
 
100 
 
 (86)  Agilent Technologies (2012), Feature Extraction Software [online]. Available from: 
http://www.genomics.agilent.com/CollectionSubpage.aspx?PageType=Product&SubPageTyp
e=ProductDetail&PageID=1379 [Downloaded 03.04.2012].  
 
 (87)  Agilent Technologies Inc. Agilent Feature Extraction Software Referance Guide. Seventh 
Edition. 2009.  
 
 (88)  Agilent Technologies Inc. Agilent RNA 6000 Nano Kit Guide.  2006.  
 
 (89)  Agilent Technologies Inc. Agilent RNA 6000 Nano Kit Quick Start Guide.  2007.  
 
 (90)  NanoDrop Technologies Inc. ND-1000 Spectrophotometer V3.5 User's Manual. Rev. 7. 2007.  
 
 (91)  Agilent Technologies (2012), GeneSpringGX Manual [online]. Available from: 
http://www.chem.agilent.com/cag/bsp/products/gsgx/manuals/genespring-manual.pdf 
[Downloaded 15.04.2012].  
 
 (92)  Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A et al. Repeated observation of 
breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A 
2003 July 8;100(14):8418-23. 
 (93)  Chu G, Li J, Narasimhan B, Tibshirani R, Tusher V (2012), SAM "Significant Analysis of 
Microarrays" Users guide and technical document Release 4.0 [online]. Available from: 
http://www-stat.stanford.edu/~tibs/SAM/sam.pdf [Downloaded 16.04.2012].  
 
 (94)  Lynn KD, Udugamasooriya DG, Roland CL, Castrillon DH, Kodadek TJ, Brekken RA. 
GU81, a VEGFR2 antagonist peptoid, enhances the anti-tumor activity of doxorubicin in the 
murine MMTV-PyMT transgenic model of breast cancer. BMC Cancer 2010 July 
30;10:397.:397. 
 (95)  Miller KD, Sweeney CJ, Sledge GW, Jr. Redefining the target: chemotherapeutics as 
antiangiogenics. J Clin Oncol 2001 February 15;19(4):1195-206. 
 (96)  Bandyopadhyay A, Wang L, Agyin J, Tang Y, Lin S, Yeh IT et al. Doxorubicin in 
combination with a small TGFbeta inhibitor: a potential novel therapy for metastatic breast 
cancer in mouse models. PLoS One 2010 April 28;5(4):e10365. 
 (97)  Biswas S, Guix M, Rinehart C, Dugger TC, Chytil A, Moses HL et al. Inhibition of TGF-beta 
with neutralizing antibodies prevents radiation-induced acceleration of metastatic cancer 
progression. J Clin Invest 2007 May;117(5):1305-13. 
 (98)  Djonov V, Cresto N, Aebersold DM, Burri PH, Altermatt HJ, Hristic M et al. Tumor cell 
specific expression of MMP-2 correlates with tumor vascularisation in breast cancer. Int J 
Oncol 2002 July;21(1):25-30. 
 (99)  Duffy MJ, Maguire TM, Hill A, McDermott E, O'Higgins N. Metalloproteinases: role in 
breast carcinogenesis, invasion and metastasis. Breast Cancer Res 2000;2(4):252-7. 
 (100)  Zitvogel L, Apetoh L, Ghiringhelli F, Andre F, Tesniere A, Kroemer G. The anticancer 
immune response: indispensable for therapeutic success? J Clin Invest 2008 
June;118(6):1991-2001. 
101 
 
 (101)  Sauter KA, Wood LJ, Wong J, Iordanov M, Magun BE. Doxorubicin and daunorubicin induce 
processing and release of interleukin-1beta through activation of the NLRP3 inflammasome. 
Cancer Biol Ther 2011 June 15;11(12):1008-16. 
 (102)  Takebe N, Harris PJ, Warren RQ, Ivy SP. Targeting cancer stem cells by inhibiting Wnt, 
Notch, and Hedgehog pathways. Nat Rev Clin Oncol 2011 February;8(2):97-106. 
 (103)  Dieudonne FX, Marion A, Marie PJ, Modrowski D. Targeted inhibition of TCF activity 
promotes syndecan-2 expression and sensitization to doxorubicin in osteosarcoma cells and 
bone tumors in mice. J Bone Miner Res 2012 May 1;10. 
 (104)  Flahaut M, Meier R, Coulon A, Nardou KA, Niggli FK, Martinet D et al. The Wnt receptor 
FZD1 mediates chemoresistance in neuroblastoma through activation of the Wnt/beta-catenin 
pathway. Oncogene 2009 June 11;28(23):2245-56. 
 (105)  DiMeo TA, Anderson K, Phadke P, Fan C, Perou CM, Naber S et al. A novel lung metastasis 
signature links Wnt signaling with cancer cell self-renewal and epithelial-mesenchymal 
transition in basal-like breast cancer. Cancer Res 2009 July 1;69(13):5364-73. 
 (106)  Chalhoub N, Baker SJ. PTEN and the PI3-kinase pathway in cancer. Annu Rev Pathol 
2009;4:127-50.:127-50. 
 (107)  Wan X, Li J, Xie X, Lu W. PTEN augments doxorubicin-induced apoptosis in PTEN-null 
Ishikawa cells. Int J Gynecol Cancer 2007 July;17(4):808-12. 
 (108)  Gottesman MM, Fojo T, Bates SE. Multidrug resistance in cancer: role of ATP-dependent 
transporters. Nat Rev Cancer 2002 January;2(1):48-58. 
 (109)  Song S, Wientjes MG, Gan Y, Au JL. Fibroblast growth factors: an epigenetic mechanism of 
broad spectrum resistance to anticancer drugs. Proc Natl Acad Sci U S A 2000 July 
18;97(15):8658-63. 
 (110)  Brady CA, Attardi LD. p53 at a glance. J Cell Sci 2010 August 1;123(Pt 15):2527-32. 
 (111)  Aas T, Borresen AL, Geisler S, Smith-Sorensen B, Johnsen H, Varhaug JE et al. Specific P53 
mutations are associated with de novo resistance to doxorubicin in breast cancer patients. Nat 
Med 1996 July;2(7):811-4. 
 (112)  Dunkern TR, Wedemeyer I, Baumgartner M, Fritz G, Kaina B. Resistance of p53 knockout 
cells to doxorubicin is related to reduced formation of DNA strand breaks rather than impaired 
apoptotic signaling. DNA Repair (Amst) 2003 January 2;2(1):49-60. 
 (113)  Dart DA, Picksley SM, Cooper PA, Double JA, Bibby MC. The role of p53 in the 
chemotherapeutic responses to cisplatin, doxorubicin and 5-fluorouracil treatment. Int J Oncol 
2004 January;24(1):115-25. 
 (114)  Li L, Davie JR. The role of Sp1 and Sp3 in normal and cancer cell biology. Ann Anat 2010 
September;20;192(5):275-83. 
 (115)  Black AR, Black JD, Azizkhan-Clifford J. Sp1 and kruppel-like factor family of transcription 
factors in cell growth regulation and cancer. J Cell Physiol 2001 August;188(2):143-60. 
 (116)  Wang F, Zhu Y, Huang Y, McAvoy S, Johnson WB, Cheung TH et al. Transcriptional 
repression of WEE1 by Kruppel-like factor 2 is involved in DNA damage-induced apoptosis. 
Oncogene 2005 June 2;24(24):3875-85. 
 (117)  Rajkumar T, Yamuna M. Multiple pathways are involved in drug resistance to doxorubicin in 
an osteosarcoma cell line. Anticancer Drugs 2008 March;19(3):257-65. 
102 
 
 (118)  Singal PK, Iliskovic N. Doxorubicin-induced cardiomyopathy. N Engl J Med 1998 September 
24;339(13):900-5. 
 (119)  Simunek T, Sterba M, Popelova O, Adamcova M, Hrdina R, Gersl V. Anthracycline-induced 
cardiotoxicity: overview of studies examining the roles of oxidative stress and free cellular 
iron. Pharmacol Rep 2009 January;61(1):154-71. 
 (120)  Lal S, Mahajan A, Chen WN, Chowbay B. Pharmacogenetics of target genes across 
doxorubicin disposition pathway: a review. Curr Drug Metab 2010 January;11(1):115-28. 
 (121)  Lee SC, Xu X, Lim YW, Iau P, Sukri N, Lim SE et al. Chemotherapy-induced tumor gene 
expression changes in human breast cancers. Pharmacogenet Genomics 2009 
March;19(3):181-92. 
 (122)  Stolboushkina EA, Garber MB. Eukaryotic type translation initiation factor 2: structure-
functional aspects. Biochemistry (Mosc ) 2011 March;76(3):283-94. 
 (123)  Bonzo JA, Ferry CH, Matsubara T, Kim JH, Gonzalez FJ. Suppression of hepatocyte 
proliferation by hepatocyte nuclear factor 4alpha in adult mice. J Biol Chem 2012 March 
2;287(10):7345-56. 
 (124)  Albihn A, Johnsen JI, Henriksson MA. MYC in oncogenesis and as a target for cancer 
therapies. Adv Cancer Res 2010;107:163-224.:163-224. 
 (125)  Westermark UK, Wilhelm M, Frenzel A, Henriksson MA. The MYCN oncogene and 
differentiation in neuroblastoma. Semin Cancer Biol 2011 October;21(4):256-66. 
 (126)  Vita M, Henriksson M. The Myc oncoprotein as a therapeutic target for human cancer. Semin 
Cancer Biol 2006 August;16(4):318-30. 
 (127)  Faneyte IF, Schrama JG, Peterse JL, Remijnse PL, Rodenhuis S, van de Vijver MJ. Breast 
cancer response to neoadjuvant chemotherapy: predictive markers and relation with outcome. 
Br J Cancer 2003 February 10;88(3):406-12. 
 (128)  Brigstock DR. Regulation of angiogenesis and endothelial cell function by connective tissue 
growth factor (CTGF) and cysteine-rich 61 (CYR61). Angiogenesis 2002;5(3):153-65. 
 (129)  Chien W, O'Kelly J, Lu D, Leiter A, Sohn J, Yin D et al. Expression of connective tissue 
growth factor (CTGF/CCN2) in breast cancer cells is associated with increased migration and 
angiogenesis. Int J Oncol 2011 June;38(6):1741-7. 
 (130)  Koike Folgueira MA, Brentani H, Carraro DM, De Camargo Barros FM, Hirata Katayama 
ML, Santana de Abreu AP et al. Gene expression profile of residual breast cancer after 
doxorubicin and cyclophosphamide neoadjuvant chemotherapy. Oncol Rep 2009 
October;22(4):805-13. 
 (131)  Lipscomb EA, Mercurio AM. Mobilization and activation of a signaling competent 
alpha6beta4integrin underlies its contribution to carcinoma progression. Cancer Metastasis 
Rev 2005 September;24(3):413-23. 
 (132)  Nikolopoulos SN, Blaikie P, Yoshioka T, Guo W, Giancotti FG. Integrin beta4 signaling 
promotes tumor angiogenesis. Cancer Cell 2004 November;6(5):471-83. 
 (133)  Arnaldez FI, Helman LJ. Targeting the insulin growth factor receptor 1. Hematol Oncol Clin 
North Am 2012 June;26(3):527-42. 
103 
 
 (134)  D'cunja J, Shalaby T, Rivera P, von BA, Patti R, Heppner FL et al. Antisense treatment of 
IGF-IR induces apoptosis and enhances chemosensitivity in central nervous system atypical 
teratoid/rhabdoid tumours cells. Eur J Cancer 2007 July;43(10):1581-9. 
 (135)  Gooch JL, Van Den Berg CL, Yee D. Insulin-like growth factor (IGF)-I rescues breast cancer 
cells from chemotherapy-induced cell death--proliferative and anti-apoptotic effects. Breast 
Cancer Res Treat 1999 July;56(1):1-10. 
 (136)  Sardao VA, Oliveira PJ, Holy J, Oliveira CR, Wallace KB. Morphological alterations induced 
by doxorubicin on H9c2 myoblasts: nuclear, mitochondrial, and cytoskeletal targets. Cell Biol 
Toxicol 2009 June;25(3):227-43. 
 (137)  Medic S, Ziman M. PAX3 across the spectrum: from melanoblast to melanoma. Crit Rev 
Biochem Mol Biol 2009 June;44(2-3):85-97. 
 (138)  Robson EJ, He SJ, Eccles MR. A PANorama of PAX genes in cancer and development. Nat 
Rev Cancer 2006 January;6(1):52-62. 
 (139)  Underwood TJ, Amin J, Lillycrop KA, Blaydes JP. Dissection of the functional interaction 
between p53 and the embryonic proto-oncoprotein PAX3. FEBS Lett 2007 December 
22;581(30):5831-5. 
 (140)  O'Malley S, Su H, Zhang T, Ng C, Ge H, Tang CK. TOB suppresses breast cancer 
tumorigenesis. Int J Cancer 2009 October 15;125(8):1805-13. 
 (141)  Cheang MC, Chia SK, Voduc D, Gao D, Leung S, Snider J et al. Ki67 index, HER2 status, 
and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst 2009 
May;20;101(10):736-50. 
 (142)  Rakha EA, Reis-Filho JS, Ellis IO. Basal-like breast cancer: a critical review. J Clin Oncol 
2008 May;20;26(15):2568-81. 
 
 
 
 
 
 
 
 
 
 
 
 
 
104 
 
Appendix A: Reagents and equipment 
 
Table 14. Reagents and equipment used in this thesis. 
 
 
Name Supplier Catalog nr./Part nr. 
Spike-Mix Agilent Technologies 5188-5282 
Dilution Buffer Agilent Technologies 5188-5282 
T7 Promotor Primer Agilent Technologies 5190-2305 
5X First Stand Buffer Agilent Technologies 5190-2305 
0.1 M DTT Agilent Technologies 5190-2305 
10 mM dNTP Mix Agilent Technologies 5190-2305 
AffinityScript RNase Block Mix Agilent Technologies 5190-2305 
5X Transcription Buffer Agilent Technologies 5190-2305 
NTP Mix Agilent Technologies 5190-2305 
T7 RNA Polymerase Blend Agilent Technologies 5190-2305 
Nuclease-free Water Agilent Technologies 5190-2305 
Cyanine 3-CTP Agilent Technologies 5190-2305 
RNeasy Mini Spin Columns Qiagen 74106 
Collection Tubes Qiagen 74106 
RNase-free Buffers (RLT, RPE) Qiagen 74106 
2X Hi-RPM Hybridization Buffer Agilent Technologies 5188-5242 
25X Fragmentation Buffer Agilent Technologies 5188-5242 
10X Gene Blocking Agent Agilent Technologies 5188-5242 
Microarray hybridization chamber 
assemblies 
Agilent Technologies G2534-60001 
Microarray Gasket slide Agilent Technologies G2534-60011 
Human GE 4x44 Microarray Agilent Technologies G4112F 
Gene Expression Wash Buffer 1 Agilent Technologies 5188-5327 
Gene Expression Wash Buffer 2 Agilent Technologies 5188-5327 
Triton X-102 (10%) Agilent Technologies 5188-5327 
RNaseZAP Applied Biosystems AM9780 
RNase-free water Invitrogen 10977-035 
Agilent RNA 6000 Nano Chip Agilent Technologies 5067-1511 
Agilent RNA 6000 Ladder Agilent Technologies 5067-1511 
RNA Nano Dye Concentrate Agilent Technologies 5067-1511 
Agilent RNA 6000 Nano Marker Agilent Technologies 5067-1511 
Agilent RNA 6000 Nano Gel Matrix Agilent Technologies 5067-1511 
Filters for Gel Matrix Agilent Technologies 5185-5990  
Chip Priming Station  Agilent Technologies 5065-4401 
Agilent Syringe Kit Agilent Technologies G2938-68706 
Ethanol (>96%) Antibac AS 6000068 
 
